Naval G. Daver, M.D.

Peer-Reviewed Articles

1. Jen WY, Kantarjian H, Kadia TM, DiNardo CD, Issa GC, Short NJ, Yilmaz M, Borthakur G, Ravandi F, Daver NG. Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease. Br J Haematol. e-Pub 2024. PMID: 38724457.
2. Daver NG, Montesinos P, DeAngelo DJ, Wang ES, Papadantonakis N, Todisco E, Sweet KL, Pemmaraju N, Lane AA, Torres-Miñana L, Thompson JE, Konopleva MY, Sloss CM, Watkins K, Bedse G, Du Y, Malcolm KE, Zweidler-McKay PA, Kantarjian HM. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study. Lancet Oncol 25(3):388-399, 2024. PMID: 38423051.
3. Daver NG Craddock C. Moving Toward Total Therapy in AML: Personalized Treatments Improve Post-Transplant Outcome. J Clin Oncol:JCO2400006. e-Pub 2024. PMID: 38471058.
4. Short NJ, Daver NG, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol:JCO2301911. e-Pub 2024. PMID: 38277619.
5. Yacoub A, Borate U, Rampal RK, Ali H, Wang ES, Gerds AT, Hobbs GS, Kremyanskaya M, Winton EF, O'Connell C, Goel S, Oh ST, Schiller GJ, McCloskey J, Palmer JM, Holmes H, Hager S, Assad A, Erickson-Viitanen S, Zhou F, Daver NG. Phase 2 study of add-on parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib: Final results. Blood Adv. e-Pub 2024. PMID: 38290135.
6. Konopleva MY, Dail M, Daver NG, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Dunshee D, Hamidi H, Ott MG, Hong WJ, Andreeff M. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial. Clin Lymphoma Myeloma Leuk. e-Pub 2024. PMID: 38378362.
7. Subklewe M, Bücklein V, Sallman D, Daver NG. Novel immunotherapies in the treatment of AML: is there hope?. Hematology Am Soc Hematol Educ Program 2023(1):691-701, 2023. PMID: 38066884.
8. Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, Mannis G, Chai-Ho W, Tanaka TN, Bradley TJ, Jeyakumar D, Wang ES, Sweet K, Kantarjian HM, Garcia-Manero G, Komrokji R, Xing G, Ramsingh G, Renard C, Zeidner JF, Sallman DA. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. J Clin Oncol:JCO2202604. e-Pub 2023. PMID: 37703506.
9. Yilmaz M, Daver NG. Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia. Lancet Haematol 10(8):e559-e561, 2023. PMID: 37532412.
10. Shallis RM, Daver NG, Altman JK, Komrokji RS, Pollyea DA, Badar T, Bewersdorf JP, Bhatt VR, de Botton S, de la Fuente Burguera A, Carraway HE, Desai P, Dillon R, Duployez N, El Chaer F, Fathi AT, Freeman SD, Gojo I, Grunwald MR, Jonas BA, Konopleva M, Lin TL, Mannis GN, Mascarenhas J, Michaelis LC, Mims AS, Montesinos P, Pozdnyakova O, Pratz KW, Schuh AC, Sekeres MA, Smith CC, Stahl M, Subklewe M, Uy GL, Voso MT, Walter RB, Wang ES, Zeidner JF, Žucenka A, Zeidan AM. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. Lancet Haematol. e-Pub 2023. PMID: 37572683.
11. Senapati J, Fiskus WC, Daver NG, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Phase 1 Results of Bromodomain and Extraterminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res. e-Pub 2023. PMID: 37585491.
12. Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, Flinn IW, Pollyea DA, Kambhampati S, Tanaka TN, Zeidner JF, Garcia-Manero G, Jeyakumar D, Komrokji R, Lancet J, Kantarjian HM, Gu L, Zhang Y, Tan A, Chao M, O'Hear C, Ramsingh G, Lal I, Vyas P, Daver NG. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. J Clin Oncol 41(15):JCO2201794, 2023. e-Pub 2023. PMID: 36888930.
13. Daver NG, Iqbal S, Huang J, Renard C, Lin J, Pan Y, Williamson M, Ramsingh G. Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion. Am J Hematol. e-Pub 2023. PMID: 37139921.
14. Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Green C, Ott MG, Hong WJ, Konopleva MY, Andreeff M. Venetoclax and idasanutlin in relapsed/refractory AML: a non-randomized, open-label phase 1b trial. Blood 141(11):1265-1276, 2023. e-Pub 2022. PMID: 36265087.
15. Daver NG, Iqbal S, Renard C, Chan RJ, Hasegawa K, Hu H, Tse P, Yan J, Zoratti MJ, Xie F, Ramsingh G. Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis. J Hematol Oncol 16(1):19, 2023. e-Pub 2023. PMID: 36879351.
16. Yap TA, Daver NG, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29(1):115-126, 2023. e-Pub 2023. PMID: 36658425.
17. Shallis RM, Daver NG, Altman JK, Hasserjian RP, Kantarjian HM, Platzbecker U, Santini V, Wei AH, Sallman DA, Zeidan AM. TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity. Cancer 129(2):175-180, 2023. e-Pub 2022. PMID: 36397669.
18. Aminu M, Daver NG Godoy MCB, Shroff G, Wu C, Torre-Sada LF, Goizueta A, Shannon VR, Faiz SA, Altan M, Garcia-Manero G, Kantarjian H, Ravandi-Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Naing A, Kim ST, Kontoyiannis DP, Khawaja F, Chung C, Wu J, Sheshadri A. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. Front Immunol 14:1249511, 2023. e-Pub 2023. PMID: 37841255.
19. Maiti A, Daver NG. Eprenetapopt in the Post-Transplant Setting: Mechanisms and Future Directions. J Clin Oncol 40(34):3994-3997, 2022. e-Pub 2022. PMID: 36070541.
20. Daver NG, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. J Clin Oncol 40(35):4048-4059, 2022. e-Pub 2022. PMID: 35849791.
21. Daver NG, Jonas BA, Medeiros BC, Patil U, Yan M. Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia. Leuk Lymphoma 63(11):2711-2714, 2022. e-Pub 2022. PMID: 35834732.
22. Fiskus W, Daver NG, Boettcher S, Mill CP, Sasaki K, Birdwell CE, Davis JA, Das K, Takahashi K, Kadia TM, DiNardo CD, Burrows F, Loghavi S, Khoury JD, Ebert BL, Bhalla KN. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia 36(11):2729-2733, 2022. e-Pub 2022. PMID: 36151141.
23. Daver NG, Maiti A, Kadia TM, Vyas P, Majeti R, Wei AH, Garcia-Manero G, Craddock C, Sallman DA, Kantarjian HM. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. Cancer Discov 12(11):2516-2529, 2022. PMID: 36218325.
24. Yacoub A, Borate U, Rampal R, Ali H, Wang E, Gerds A, Hobbs G, Kremyanskaya M, Winton E, O'Connell C, Goel S, Oh S, Schiller G, Assad A, Erickson-Viitanen S, Zhou F, Daver NG. MPN-075 Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Low Versus Higher Baseline Platelet Counts: A Subgroup Analysis of Data From a Phase 2 Study. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S324, 2022. PMID: 36163982.
25. Sheshadri A, Goizueta AA, Shannon VR, London D, Garcia-Manero G, Kantarjian HM, Ravandi-Kashani F, Kadia TM, Konopleva MY, DiNardo CD, Pierce S, Zarifa A, Albittar AA, Zhong LL, Akhmedzhanov FO, Arain MH, Alfayez M, Alotaibi A, Altan M, Naing A, Mendoza TR, Godoy MCB, Shroff G, Kim ST, Faiz SA, Kontoyiannis DP, Khawaja F, Jennings K, Daver NG. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer 128(14):2736-2745, 2022. e-Pub 2022. PMID: 35452134.
26. El Hussein S, Daver NG, Liu JL, Kornblau S, Fang H, Konoplev S, Kantarjian H, Khoury JD. Microsatellite Instability Assessment by Immunohistochemistry in Acute Myeloid Leukemia: A Reappraisal and Review of the Literature. Clin Lymphoma Myeloma Leuk 22(6):e386-e391, 2022. e-Pub 2021. PMID: 34980577.
27. Desikan SP, Daver NG, DiNardo C, Kadia T, Konopleva M, Ravandi F. Resistance to targeted therapies: delving into FLT3 and IDH. Blood Cancer J 12(6):91, 2022. e-Pub 2022. PMID: 35680852.
28. Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver NG. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77, 2022. e-Pub 2022. PMID: 35501304.
29. Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver NG. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma:1-10. e-Pub 2022. PMID: 35442137.
30. Saxena K, DiNardo C, Daver NG, Konopleva M. Harnessing Apoptosis in AML. Clin Lymphoma Myeloma Leuk 22(3):133-139, 2022. e-Pub 2021. PMID: 34602371.
31. Venugopal S, Borthakur G, Daver NG, DiNardo CD, Pemmaraju N, Short NJ, Abbas HA, Garcia-Manero G, Konopleva MY, Ravandi F, Kadia TM. Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy. Blood Adv. e-Pub 2022. PMID: 35201293.
32. Maiti A, Daver NG. A nonstick marrow may help to fry leukemia. Blood 139(8):1119-1121, 2022. PMID: 35201330.
33. Haddad F, Zeidan AM, Daver NG. Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia. Cancer J 28(1):43-50, 2022. PMID: 35072373.
34. Fiskus W, Boettcher S, Daver NG, Mill CP, Sasaki K, Birdwell CE, Davis JA, Takahashi K, Kadia TM, DiNardo CD, Jin Q, Qi Y, Su X, McGeehan GM, Khoury JD, Ebert BL, Bhalla KN. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J 12(1):5, 2022. e-Pub 2022. PMID: 35017466.
35. Senapati J, Daver NG, Pemmaraju N. Antibody-Drug Conjugates in Myeloid Leukemias. Cancer J 28(6):454-461, 2022. PMID: 36383908.
36. Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, Daver NG, DiNardo C, Kadia T, Garcia-Manero G, Chan T, Shah RR, Wierda WG. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia 35(11):3282-3286, 2021. e-Pub 2021. PMID: 33833386.
37. Maiti A, Daver NG. Lowering mTORC1 Drives CAR T-Cells Home in Acute Myeloid Leukemia. Clin Cancer Res 27(21):5739-5741, 2021. e-Pub 2021. PMID: 34470774.
38. Abbas HA, Alaniz Z, Mackay S, Cyr M, Zhou J, Issa GC, Alfayez M, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Konopleva M, Andreeff M, Daver NG. Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy. Blood Adv 5(22):4569-4574, 2021. PMID: 34555853.
39. Wei SC, Mancuso JJ, Daver NG, Allison JP. Checkpoint Blockade + Chemotherapy: the Right Combination for AML?. Blood Cancer Discov 2(6):551-554, 2021. e-Pub 2021. PMID: 35015675.
40. Saxena K, Herbrich SM, Pemmaraju N, Kadia TM, DiNardo CD, Borthakur G, Pierce SA, Jabbour E, Wang SA, Bueso-Ramos C, Loghavi S, Tang G, Cheung CM, Alexander L, Kornblau S, Andreeff M, Garcia-Manero G, Ravandi F, Konopleva MY, Daver NG. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer 127(20):3761-3771, 2021. e-Pub 2021. PMID: 34171128.
41. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver NG, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer 127(17):3113-3124, 2021. e-Pub 2021. PMID: 33914911.
42. Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver NG, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer 127(15):2648-2656, 2021. e-Pub 2021. PMID: 33793964.
43. Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, DiNardo CD, Kadia TM, Garcia-Manero G, Daver NG, Montalban Bravo G, Cortes JE, Ravandi F, Jabbour E. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer 127(15):2641-2647, 2021. e-Pub 2021. PMID: 33823073.
44. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver NG, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica 106(8):2121-2130, 2021. e-Pub 2021. PMID: 33853292.
45. Yilmaz M, Daver NG, Borthakur G, Kadia T, DiNardo C, Kanagal-Shamanna R, Loghavi S, Oran B, Popat UR, Pierce S, Jabbour E, Short NJ, Issa G, Ohanian M, Konopleva M, Patel K, Kantarjian H, Ravandi F. FLT3 inhibitor based induction and allogeneic stem cell transplant in CR1 improves outcomes in patients with newly diagnosed AML with very low FLT3 allelic burden. Am J Hematol 96(8):E275-E279, 2021. e-Pub 2021. PMID: 33891709.
46. Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver NG, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 96(8):914-924, 2021. e-Pub 2021. PMID: 33901324.
47. Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver NG, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica 106(7):1988-1990, 2021. e-Pub 2021. PMID: 31296578.
48. Short NJ, Konopleva M, Kadia T, Kebriaei P, Daver NG, Huang X, Masarova L, Cook R, Jain N, Jabbour E, Kantarjian H, Ravandi F. An Effective Chemotherapy-Free Regimen of Ponatinib plus Venetoclax for Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Am J Hematol 96(7):E229-E232, 2021. e-Pub 2021. PMID: 33780038.
49. Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer 127(14):2489-2499, 2021. e-Pub 2021. PMID: 33793970.
50. Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver NG, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, Genomic, and Transcriptomic Differences between Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS). Am J Hematol 96(7):E246-E249, 2021. e-Pub 2021. PMID: 33811786.
51. Daver N, Alotaibi AS, Bücklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia 35(7):1843-1863, 2021. e-Pub 2021. PMID: 33953290.
52. Abou Dalle I, Kantarjian HM, Ravandi F, Daver NG, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer 127(11):1894-1900, 2021. e-Pub 2021. PMID: 33449377.
53. Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NG, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 127(12):2025-2038, 2021. e-Pub 2021. PMID: 33740268.
54. Zeng Z, Ly C, Daver NG, Cortes J, Kantarjian HM, Andreeff M, Konopleva M. High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells. Ann Hematol 100(6):1485-1496, 2021. e-Pub 2021. PMID: 33787984.
55. Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver NG, Pemmaraju N, Verstovsek S, Champlin RE, Popat UR. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol 193(5):1004-1008, 2021. e-Pub 2021. PMID: 33821472.
56. Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Estrov Z, Yilmaz M, Daver NG, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. Clin Infect Dis 72(10):1755-1763, 2021. e-Pub 2020. PMID: 32236406.
57. Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, Kantarjian H, Estrov Z, Verstovsek S. Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk 21(5):318-327.e6, 2021. e-Pub 2021. PMID: 33551345.
58. Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Decitabine and Venetoclax for IDH1/2-mutated Acute Myeloid Leukemia. Am J Hematol 96(5):E154-E157, 2021. e-Pub 2021. PMID: 33580980.
59. Morita K, Jabbour E, Ravandi F, Borthakur G, Khoury JD, Hu S, Garcia-Manero G, Wierda W, Issa G, Daver NG, Pemmaraju N, Montalban-Bravo G, Soltysiak KA, Pierce S, Bueso-Ramos C, Cortes J, Sasaki K. Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clin Lymphoma Myeloma Leuk 21(5):338-344, 2021. e-Pub 2021. PMID: 33597098.
60. Daver NG, Salhotra A, Brandwein JM, Podoltsev NA, Pollyea DA, Jurcic JG, Assouline S, Yee K, Li M, Pourmohamad T, Samineni D, Sumiyoshi T, Vaze A, Dere RC, Ma C, Cooper J. A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. Am J Hematol 96(5):E175-E179, 2021. e-Pub 2021. PMID: 33617672.
61. Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver NG, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia 35(5):1494-1499, 2021. e-Pub 2021. PMID: 33846541.
62. Daver NG, Venugopal S, Ravandi F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J 11(5):104, 2021. e-Pub 2021. PMID: 34045454.
63. Haddad F, Daver NG. Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab. J Immunother Precis Oncol 4(2):67-71, 2021. e-Pub 2021. PMID: 35663535.
64. Wei AH, Daver NG. Taking aim at IDH in fitter patients with AML. Blood 137(13):1706-1707, 2021. PMID: 33792680.
65. Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. PMID: 33792630.
66. Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver NG, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173-2183, 2021. PMID: 33885753.
67. Masarova L, DiNardo CD, Bose P, Pemmaraju N,Daver NG, Kadia TM, Chifotides HT, Zhou L, Borthakur G, Estrov Z, Konopleva M, Verstovsek S. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv 5(8):2156-2164, 2021. PMID: 33885751.
68. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
69. Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, DiNardo CD, Daver NG, Pemmaraju N, Kantarjian H, Borthakur G. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia 35(3):691-700, 2021. e-Pub 2020. PMID: 32561839.
70. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2020. PMID: 33264443.
71. Loghavi S, DiNardo CD, Furudate K, Takahashi K, Tanaka T, Short NJ, Kadia T, Konopleva M, Kanagal-Shamanna R, Farnoud NR, Pierce S, Khoury JD, Jorgensen JL, Patel KP, Daver NG, Yilmaz M, Medeiros LJ, Kantarjian H, Ravandi F, Wang SA. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol 192(6):1054-1063, 2021. e-Pub 2021. PMID: 33618432.
72. Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver NG, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J 11(3):52, 2021. e-Pub 2021. PMID: 33677472.
73. Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov 2(2):125-134, 2021. e-Pub 2020. PMID: 33681815.
74. Reville PK, Kantarjian HM, Ravandi F, Jabbour E, DiNardo CD, Daver NG, Pemmaraju N, Ohanian M, Alvarado Y, Xiao L, Alatrash G, Loghavi S, Rausch CR, Borthakur G, Konopleva M, Cortes J, Kadia TM. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J 11(3):60, 2021. e-Pub 2021. PMID: 33731681.
75. Daver NG. Immune checkpoint inhibitors in acute myeloid leukemia. Best Pract Res Clin Haematol 34(1):101247, 2021. e-Pub 2021. PMID: 33762102.
76. Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver NG. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer 127(3):381-390, 2021. e-Pub 2020. PMID: 33119202.
77. Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver NG, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia. Am J Hematol 96(2):E50-E53, 2021. e-Pub 2020. PMID: 33156969.
78. Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver NG, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. The Leukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes. Am J Hematol 96(2):241-250, 2021. e-Pub 2020. PMID: 33180322.
79. Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
80. Kantarjian H, Kadia T, DiNardo C, Daver NG, Borthakur G, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F. Acute myeloid leukemia: current progress and future directions. Blood Cancer J 11(2):41, 2021. e-Pub 2021. PMID: 33619261.
81. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 14(1):34, 2021. e-Pub 2021. PMID: 33618754.
82. Venugopal S, Daver NG, Ravandi F. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia. Curr Hematol Malig Rep 16(1):89-96, 2021. e-Pub 2021. PMID: 33630233.
83. Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Rondon G, Whited L, Gruschkus S, Fa'ak F, Daher M, Knape C, Safa H, Shoukier M, Suarez-Almazor ME, Marcotulli M, Ludford K, Gulbis AM, Konopleva M, Ohanian M, Ravandi F, Garcia-Manero G, Oran B, Popat UR, Mehta R, Alousi AM, Daver NG Champlin R, Diab A, Al-Atrash G. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. J Immunother Cancer 9(2), 2021. PMID: 33637601.
84. Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver NG, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Treating Leukemia in the Time of COVID-19. Acta Haematol 144(2):1-13, 2021. e-Pub 2020. PMID: 32392559.
85. Cerchione C, Romano A, Daver NG, DiNardo C, Jabbour EJ, Konopleva M, Ravandi-Kashani F, Kadia T, Martelli MP, Isidori A, Martinelli G, Kantarjian H. IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. Front Oncol 11:639387, 2021. e-Pub 2021. PMID: 33898313.
86. Isidori A, Daver NG, Curti A. Editorial: The Biological Landscape of Immunotherapy in AML. Front Oncol 11:671252, 2021. e-Pub 2021. PMID: 33937085.
87. Haddad F, Daver NG. An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!. Adv Exp Med Biol 1342:273-295, 2021. PMID: 34972969.
88. Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia T, Daver NG, Pemmaraju N, Konopleva M, Borthakur G, Takahashi K, Patel K, Soltysiak KA, Chien KS, Sakurai K, Pierce S, Kantarjian HM, Garcia-Manero G. Natural History of Newly Diagnosed Myelodysplastic Syndrome with Isolated Inv(3)/t(3;3). Am J Hematol 95(12):E326-E329, 2020. e-Pub 2020. PMID: 32886803.
89. Koshy AG, Daver NG, Fathi AT. A new era of immuno-oncology in acute myeloid leukemia - antibody-based therapies and immune checkpoint inhibition. Best Pract Res Clin Haematol 33(4):101220, 2020. e-Pub 2020. PMID: 33279176.
90. Short NJ, Rafei H, Daver NG, Hwang H, Ning J, Jorgensen JL, Kadia TM, DiNardo CD, Wang SA, Jabbour E, Popat U, Oran B, Cortes J, Konopleva M, Yilmaz M, Issa GC, Kantarjian H, Ravandi F. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv 4(24):6117-6126, 2020. PMID: 33351107.
91. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver NG, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
92. Konopleva M, Martinelli G, Daver NG, Papayannidis C, Wei A, Higgins B, Ott M, Mascarenhas J, Andreeff M. MDM2 inhibition: an important step forward in cancer therapy. Leukemia 34(11):2858-2874, 2020. e-Pub 2020. PMID: 32651541.
93. Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver NG, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes J. Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia. Am J Hematol 95(11):1288-1295, 2020. e-Pub 2020. PMID: 32681739.
94. Borthakur G, Zeng Z, Cortes JE, Chen HC, Huang X, Konopleva M, Ravandi F, Kadia T, Patel KP, Daver NG, Kelly MA, McQueen T, Wang RY, Kantarjian H, Andreeff M. Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol 95(11):1296-1303, 2020. e-Pub 2020. PMID: 32697348.
95. Lachowiez C, Bannon S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, Daver NG, Borthakur G, Pemmaraju N, Ravandi F, Patel KP, Garcia-Manero G, Takahashi K, Kantarjian H, Bhalla K, DiNardo CD. Clonal Evolution and Treatment Outcomes in Hematopoietic Neoplasms Arising in Patients with Germline RUNX1 mutations. Am J Hematol 95(11):E313-E315, 2020. e-Pub 2020. PMID: 32804409.
96. Chifotides HT, Masarova L, Alfayez M, Daver NG, Alvarado Y, Jabbour E, Konopleva M, Kantarjian HM, Patel KP, DiNardo CD, Verstovsek S. Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv 4(21):5336-5342, 2020. PMID: 33112940.
97. Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver NG, Issa GC, Andreeff M, Kantarjian H, Kadia TM. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv 4(22):5681-5689, 2020. PMID: 33211826.
98. Paul S, Jammal N, Akhave N, Aung PP, Loghavi S, Jain N, Garcia-Manero G, Borthakur G, Verstovsek S, Jabbour E, Adachi J, Masarova L, Daver NG, Ravandi F, Pemmaraju N. Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. Br J Haematol 191(1):e10-e13, 2020. e-Pub 2020. PMID: 32686139.
99. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Wierda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
100. Daver NG, Wei AH, Pollyea DA, Fathi AT, Vyas P, DiNardo CD. New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J 10(10):107, 2020. e-Pub 2020. PMID: 33127875.
101. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 13(1):132, 2020. e-Pub 2020. PMID: 33032648.
102. Short NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel KP, Konopleva M, Papageorgiou I, Pemmaraju N, Borthakur G, Ravandi F, DiNardo CD, Kadia TM, Kantarjian H, Lamba JK, Daver NG. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol 95(9):E225-E228, 2020. e-Pub 2020. PMID: 32356320.
103. Saxena K, DiNardo C, Daver NG, Konopleva M. Harnessing Apoptosis in AML. Clin Lymphoma Myeloma Leuk 20 Suppl 1:S61-S64, 2020. PMID: 32862872.
104. Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver NG, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma:1-8. e-Pub 2020. PMID: 32755333.
105. Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver NG, Burger J, DiNardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Am J Hematol 95(7):734-739, 2020. e-Pub 2020. PMID: 32170867.
106. Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 7(7):e523-e533, 2020. PMID: 32589978.
107. Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, Sasaki K, Kantarjian HM, Estrov Z, Verstovsek S. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer. e-Pub 2020. PMID: 32697338.
108. Thakral B, Daver NG, Tang Z, Patel KP, Ok CY, Loghavi S, Khoury JD, Alotaibi AS, Konopleva M, Yilmaz M, Medeiros LJ. Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. Leuk Lymphoma:1-4. e-Pub 2020. PMID: 32696696.
109. Galloway-Peña JR, Shi Y, Peterson CB, Sahasrabhojane P, Gopalakrishnan V, Brumlow CE, Daver NG, Alfayez M, Boddu PC, Khan MAW, Wargo JA, Do KA, Jenq RR, Kontoyiannis DP, Shelburne SA. Gut Microbiome Signatures are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia. Clin Infect Dis 71(1):63-71, 2020. e-Pub 2019. PMID: 31436833.
110. Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver NG, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of Acute Myeloid Leukemia with Myelodysplasia Related Changes depend on diagnostic criteria and therapy. Am J Hematol 95(6):612-622, 2020. e-Pub 2020. PMID: 32112433.
111. Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, DiNardo CD, Daver NG, Short NJ, Alvarado Y, Cortes J, Kim C, Kelsh M, Katz A, Williams R, Yang Z, Mehta B, Kantarjian H. Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 2020. PMID: 32792304.
112. Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver NG. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer 126(10):2193-2205, 2020. e-Pub 2020. PMID: 32125707.
113. Abou Dalle I, Ghorab A, Patel K, Wang X, Hwang H, Cortes J, Issa GC, Yalniz F, Sasaki K, Chihara D, Price A, Kadia T, Pemmaraju N, Daver NG, DiNardo C, Ravandi F, Kantarjian HM, Borthakur G. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J 10(5):48, 2020. e-Pub 2020. PMID: 32366841.
114. Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver NG, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J 10(5):47, 2020. e-Pub 2020. PMID: 32366832.
115. Lachowiez CA, Loghavi S, Kadia TM, Daver NG, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv 4(7):1311-1320, 2020. PMID: 32251497.
116. Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv 4(8):1690-1699, 2020. PMID: 32330243.
117. Daver NG. A bispecific approach to improving CAR T cells in AML. Blood 135(10):703-704, 2020. PMID: 32135017.
118. Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, Bashir Q, Alousi A, Mehta R, Oran B, Popat U, Hosing C, Olson A, Daver NG, Konopleva M, Champlin RE. Is There an Optimal Conditioning for Older Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation?. Blood 135(6):449-452, 2020. e-Pub 2019. PMID: 31826244.
119. Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, Daver NG. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. Cancer Discov. e-Pub 2020. PMID: 32014868.
120. Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver NG, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv 4(3):482-495, 2020. PMID: 32027746.
121. Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. e-Pub 2020. PMID: 32099037.
122. Pankow JD, Richard-Carpentier G, Daver NG, Glass WF, Kala J. Unique case of ANCA-negative pauci-immune necrotizing glomerulonephritis with diffuse alveolar hemorrhage, potentially associated with midostaurin. CEN Case Rep. e-Pub 2020. PMID: 31955389.
123. Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K, Marx K, Daver NG, Kadia TM, Konopleva MY, Masarova L, Borthakur G, DiNardo CD, Naqvi K, Pierce S, Kantarjian HM, Short NJ. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol 143(6):1-7, 2020. e-Pub 2020. PMID: 32289808.
124. Daver NG, Price A, Benton CB, Patel K, Zhang W, Konopleva M, Pemmaraju N, Takahashi K, Andreeff M, Borthakur G. First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations. Front Oncol 10:1538, 2020. e-Pub 2020. PMID: 32984009.
125. Alotaibi AS, Yilmaz M, Loghavi S, DiNardo C, Borthakur G, Kadia TM, Thakral B, Pemmaraju N, Issa GC, Konopleva M, Short NJ, Patel K, Tang G, Ravandi F, Daver NG. Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series. Front Oncol 10:588876, 2020. e-Pub 2020. PMID: 33194747.
126. Samra B, Konopleva M, Isidori A, Daver NG, DiNardo C. Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions. Front Oncol 10:562558, 2020. e-Pub 2020. PMID: 33251134.
127. Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Ruiz Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver NG. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. Front Immunol 11:590494, 2020. e-Pub 2021. PMID: 33552049.
128. Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver NG, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol 10:582213, 2020. e-Pub 2021. PMID: 33585199.
129. Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver NG, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation. Am J Hematol 94(12):1382-1387, 2019. e-Pub 2019. PMID: 31595538.
130. Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver NG, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer 125(21):3755-3766, 2019. e-Pub 2019. PMID: 31310323.
131. Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, Autio KA, Pant S, Bauer TM, Drakaki A, Daver NG, Hung A, Ratti N, McCauley S, Van Vlasselaer P, Verma R, Ferry D, Oft M, Diab A, Garon EB, Tannir NM. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol 20(11):1544-1555, 2019. e-Pub 2019. PMID: 31563517.
132. Ye MT, Wang Y, Wang SA, Pemmaraju N, Daver NG, Verstovsek S, Zhang Y, Zuo Z, Medeiros LJ, You MJ. Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leuk Lymphoma:1-4. e-Pub 2019. PMID: 31750750.
133. Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver NG, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer 125(18):3219-3224, 2019. e-Pub 2019. PMID: 31150121.
134. Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver NG, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol 94(9):984-991, 2019. e-Pub 2019. PMID: 31237017.
135. Ravandi F, Assi R, Daver NG, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol 6(9):e480-e488, 2019. e-Pub 2019. PMID: 31400961.
136. Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver NG. Emerging drug profile: CPX-351 (vyxeos) in AML. Leuk Lymphoma:1-10. e-Pub 2019. PMID: 31547736.
137. Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver NG, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer 125(15):2579-2586, 2019. e-Pub 2019. PMID: 30985931.
138. Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma 60(7):1-8, 2019. e-Pub 2019. PMID: 30632841.
139. Medeiros BC, Chan SM, Daver NG, Jonas BA, Pollyea DA. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. Am J Hematol 94(7):803-811, 2019. e-Pub 2019. PMID: 30945331.
140. Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver NG, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F. Intensive Chemotherapy (IC) is More Effective than Hypomethylating Agents (HMA) for the Treatment of Younger Patients with Myelodysplastic Syndrome (MDS) and Elevated Bone Marrow Blasts. Am J Hematol 94(7):E188-E190, 2019. e-Pub 2019. PMID: 30977182.
141. Yilmaz M, Daver NG. From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia. Drugs 79(11):1177-1186, 2019. e-Pub 2019. PMID: 31222627.
142. Daver NG, Stein E. AML: The future is now or was it yesterday?. Best Pract Res Clin Haematol 32(2):115, 2019. e-Pub 2019. PMID: 31203992.
143. Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, Kadia TM, Naqvi K, Cortes J, Konopleva M. Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. Leuk Lymphoma:1-4. e-Pub 2019. PMID: 31246142.
144. Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 125(9):1470-1481, 2019. e-Pub 2018. PMID: 30500073.
145. Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau JB, Kwari MI, Ravandi F, Anderson BD, Iizuka K, Jin C, Zhang C, Plunkett WK. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer 125(10):1665-1673, 2019. e-Pub 2019. PMID: 30668890.
146. Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver NG, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol 109(5):545-552, 2019. e-Pub 2019. PMID: 30830579.
147. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv 3(9):1533-1539, 2019. PMID: 31076409.
148. Boddu P, Jain P, Borthakur G, Verstovsek S, Garcia-Manero G, Daver NG, Kadia T, Ravandi F, Jabbour E, Cortes J, Kantarjian H. Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leuk Lymphoma:1-9. e-Pub 2019. PMID: 31125272.
149. Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Bottecelli Koller P, Jacamo R, Burks JK, DiNardo C, Daver NG, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. e-Pub 2019. PMID: 31123034.
150. Angelova E, Audette C, Kovtun Y, Daver NG, Wang SA, Pierce S, Konoplev SN, Khogeer H, Jorgensen JL, Konopleva M, Zweidler-McKay PA, Medeiros LJ, Kantarjian HM, Jabbour EJ, Khoury JD. CD123 expression patterns and selective targeting with a CD123-specific antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. Haematologica 104(4):749-755, 2019. e-Pub 2018. PMID: 30361418.
151. Boddu PC, Kadia TM, Garcia-Manero G, Cortes J, Alfayez M, Borthakur G, Konopleva M, Jabbour EJ, Daver NG, DiNardo CD, Naqvi K, Yilmaz M, Short NJ, Pierce S, Kantarjian HM, Ravandi F. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Cancer 125(7):1091-1100, 2019. e-Pub 2018. PMID: 30521114.
152. Daver NG, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study. Cancer Discov 9(3):370-383, 2019. e-Pub 2018. PMID: 30409776.
153. Benton CB, Chien KS, Tefferi A, Rodriguez J, Ravandi F, Daver NG, Jabbour E, Jain N, Alvarado Y, Kwari M, Pierce S, Maiti A, Hornbaker M, Santos MA, Martinez S, Siguero M, Zblewski D, Al-Kali A, Hogan WJ, Kantarjian H, Pardanani A, Garcia-Manero G. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. Hematol Oncol 37(1):96-102, 2019. e-Pub 2018. PMID: 30153704.
154. Daver NG, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 33(2):299-312, 2019. e-Pub 2019. PMID: 30651634.
155. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver NG, Ohanian M, DiNardo C.D., Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2018. PMID: 30545576.
156. Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver NG, Konopleva M, DiNardo CD, Kadia T, Pemmaraju N, Jabbour E, Cortes J. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. J Hematol Oncol 12(1):1, 2019. e-Pub 2019. PMID: 30606227.
157. Shroff GS, Truong MT, Carter BW, Benveniste MF, Kanagal-Shamanna R, Rauch G, Viswanathan C, Boddu PC, Daver NG, Wu CC. Leukemic Involvement in the Thorax. Radiographics 39(1):44-61, 2019. PMID: 30620703.
158. Daver NG. The Emerging Profile of Immunotherapy Approaches in the Treatment of AML. Oncology (Williston Park) 33(1):28-32, 2019. e-Pub 2019. PMID: 30731016.
159. Short NJ, Kantarjian H, Ravandi F, Daver NG. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther Adv Hematol 10:2040620719827310, 2019. e-Pub 2019. PMID: 30800259.
160. Alfayez M, Ivan D, Pemmaraju N, Daver NG, DiNardo CD. Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 30957058.
161. Abbas HA, Alfayez M, Kadia T, Ravandi-Kashani F, Daver NG. Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection. Cancer Manag Res 11:8817-8828, 2019. e-Pub 2019. PMID: 31632141.
162. Oran B, Daver NG. Check-Point Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double-Edge Sword. Biol Blood Marrow Transplant 25(1):e1-e2, 2019. e-Pub 2018. PMID: 30500441.
163. Jabbour E, Short NJ, Ravandi F, Huang X, Daver NG, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol 5(12):e618-e627, 2018. PMID: 30501869.
164. Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 2018. PMID: 30635233.
165. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver NG, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia 32(11):2388-2398, 2018. e-Pub 2018. PMID: 29769624.
166. Assi R, Gur HD, Loghavi S, Konoplev SN, Konopleva M, Daver NG, Tashakori M, Kadia T, Routbort M, Salem A, Kanagal-Shamanna R, Quesada A, Jabbour EJ, Kornblau SM, Medeiros LJ, Kantarjian H, Khoury JD. P53 Protein Overexpression in De Novo Acute Myeloid Leukemia Patients with Normal Diploid Karyotype Correlates with FLT3 Internal Tandem Duplication and Worse Relapse-Free Survival. Am J Hematol 93(11):1376-1383, 2018. e-Pub 2018. PMID: 30117185.
167. Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Mutational landscape of myelodysplastic/myeloproliferative neoplasm - unclassifiable (MDS/MPN-U). Blood 132(19):2100-2103, 2018. e-Pub 2018. PMID: 30242087.
168. Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, DiNardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TM. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer 124(21):4192-4201, 2018. e-Pub 2018. PMID: 30307606.
169. Zhang W, Ly C, Ishizawa J, Mu H, Ruvolo V, Shacham S, Daver NG, Andreeff M. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica 103(10):1642-1653, 2018. e-Pub 2018. PMID: 29773601.
170. Yalniz FF, Daver NG, Rezvani K, Kornblau S, Ohanian M, Borthakur G, DiNardo CD, Konopleva M, Burger J, Gasior Y, Pierce S, Kantarjian H, Garcia-Manero G. A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 18(10):658-663.e2, 2018. e-Pub 2018. PMID: 30001986.
171. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver NG. A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis. Blood 132(16):1664-1674, 2018. e-Pub 2018. PMID: 30185431.
172. Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, DiNardo CD, Konopleva M, Daver NG, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, Kadia T. Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Leuk Lymphoma 59(9):1-4, 2018. e-Pub 2018. PMID: 29338567.
173. Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver NG, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Sorafenib Combined with 5-azacytidine (AZA) in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia (AML). Am J Hematol 93(9):1136-1141, 2018. e-Pub 2018. PMID: 30028037.
174. Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver NG, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol 5(9):e411-e421, 2018. e-Pub 2018. PMID: 30115541.
175. Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, Daver NG, Alvarado Y, Konopleva M, Kebriaei P, Wierda WG, DiNardo CD, Bivins C, McCue D, Richie MA, Ravandi F. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol 182(3):442-444, 2018. e-Pub 2017. PMID: 28616864.
176. Lyle L, Daver NG. Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway. Am J Manag Care 24(16 Suppl):S356-S365, 2018. PMID: 30132679.
177. Wiese M, Daver NG. Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemia. Am J Manag Care 24(16 Suppl):S347-S355, 2018. PMID: 30132678.
178. Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver NG. Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma 59(7):1-5, 2018. e-Pub 2017. PMID: 29119847.
179. Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, Daver NG, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur G. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124(13):2758-2765, 2018. e-Pub 2018. PMID: 29660836.
180. Ruvolo PP, Ruvolo VR, Burks JK, Qiu Y, Wang RY, Shpall EJ, Mirandola L, Hail N, Zeng Z, McQueen T, Daver NG, Post SM, Chiriva-Internati M, Kornblau SM, Andreeff M. Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865(7):959-969, 2018. e-Pub 2018. PMID: 29655803.
181. Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfoos T, Morlacchi P, Ackroyd J, Agip AA, Al-Atrash G, Asara J, Bardenhagen J, Carrillo CC, Carroll C, Chang E, Ciurea S, Cross JB, Czako B, Deem A, Daver NG, de Groot JF, Dong JW, Feng N, Gao G, Gay J, Do MG, Greer J, Giuliani V, Han J, Han L, Henry VK, Hirst J, Huang S, Jiang Y, Kang Z, Khor T, Konoplev S, Lin YH, Liu G, Lodi A, Lofton T, Ma H, Mahendra M, Matre P, Mullinax R, Peoples M, Petrocchi A, Rodriguez-Canale J, Serreli R, Shi T, Smith M, Tabe Y, Theroff J, Tiziani S, Xu Q, Zhang Q, Muller F, DePinho RA, Toniatti C, Draetta GF, Heffernan TP, Konopleva M, Jones P, Di Francesco ME, Marszalek JR. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med 24(7):1036-1046, 2018. e-Pub 2018. PMID: 29892070.
182. Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, Chen J, Wallis W, Cao K, Konopleva M, Daver NG, Cortes J, Ravandi F, Alousi A, Ahmed S, Popat U, Parmar S, Bashir Q, Betul O, Hosing C, Shpall EJ, Rezvani K, Khouri IF, Kebriaei P, Champlin RE. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 24(6):1232-1236, 2018. e-Pub 2017. PMID: 28918304.
183. Boddu P, Oviedo SP, Rausch CR, Yam C, Daver NG, Kantarjian H, Kadia TM. PET-CT in AML-related hemophagocytic lymphohistiocytosis. Leuk Lymphoma 59(6):1-4, 2018. e-Pub 2017. PMID: 28958191.
184. Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver NG, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma 59(6):1-11, 2018. e-Pub 2017. PMID: 28972430.
185. Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer 124(12):2534-2540, 2018. e-Pub 2018. PMID: 29645075.
186. Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver NG, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol 36(18):JCO2017776757, 2018. e-Pub 2018. PMID: 29702001.
187. Daver NG, Boddu P, Garcia-Manero G, Yadav SS, Sharma P, Allison J, Kantarjian H. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia 32(5):1094-1105, 2018. e-Pub 2018. PMID: 29487386.
188. Chyla B, Daver NG, Doyle K, McKeegan E, Huang X, Ruvolo V, Wang Z, Chen K, Souers A, Leverson J, Potluri J, Boghaert E, Bhathena A, Konopleva M, Popovic R. Genetic Biomarkers Of Sensitivity and Resistance to Venetoclax Monotherapy in Patients With Relapsed Acute Myeloid Leukemia. Am J Hematol. e-Pub 2018. PMID: 29770480.
189. Boddu P, Kantarjian H, Garcia-Manero G, Allison J, Sharma P, Daver NG. The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma 59(4):1-13, 2018. e-Pub 2017. PMID: 28679300.
190. Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2017. PMID: 28718728.
191. Boddu P, Kantarjian H, Garcia-Manero G, Ravandi F, Jabbour E, Borthakur G, Daver NG, Pemmaraju N, Pierce S, Cortes J, Kadia TM. Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. Leuk Lymphoma 59(4):1-4, 2018. e-Pub 2017. PMID: 28838278.
192. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, Jain N, Daver NG, Gulbis AM, Adkins S, Rezvani K, Hwu P, Shpall EJ. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15(4):218, 2018. e-Pub 2018. PMID: 29434334.
193. Jabbour E, Düll J, Yilmaz M, Khoury JD, Ravandi F, Jain N, Einsele H, Garcia-Manero G, Konopleva M, Short NJ, Thompson PA, Wierda W, Daver NG, Cortes J, O'Brien S, Kantarjian H, Topp MS. Outcome of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia after Blinatumomab Failure: No Change in the Level of CD19 Expression. Am J Hematol 93(3):371-374, 2018. e-Pub 2017. PMID: 29178361.
194. Assi R, Kantarjian H, Ravandi F, Daver NG. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol 25(2):136-145, 2018. e-Pub 2017. PMID: 29206680.
195. DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver NG, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. Clinical Experience with the BCL2-inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies. Am J Hematol 93(3):401-407, 2018. e-Pub 2017. PMID: 29218851.
196. Masarova L, Alhuraiji A, Bose P, Daver NG, Pemmaraju N, Cortes J, Pierce S, Kantarjian H, Verstovsek S. Significance of thrombocytopenia in patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol 100(3):257-263, 2018. e-Pub 2018. PMID: 29226426.
197. Sasaki K, Kantarjian H, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver NG, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour E, Cortes JE. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer 124(6):1160-1168, 2018. e-Pub 2017. PMID: 29266206.
198. Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, DiNardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver NG. A Phase II Trial of Ruxolitinib in Combination with Azacytidine in Myelodysplastic Syndrome/Myeloproliferative Neoplasms. Am J Hematol 93(2):277-285, 2018. e-Pub 2017. PMID: 29134664.
199. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver NG, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Borthakur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 19(2):240-248, 2018. e-Pub 2018. PMID: 29352703.
200. Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget 9(11):9714-9727, 2018. e-Pub 2018. PMID: 29515765.
201. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver NG, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47-62, 2018. e-Pub 2017. PMID: 28925994.
202. Alhuraiji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, Daver NG, Kadia T, Pemmaraju N, Pierce S, Garcia-Manero G, Wierda W, Verstovsek S, Jabbour E, Cortes J. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 93(1):84-90, 2018. e-Pub 2017. PMID: 29027261.
203. Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver NG, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus Nelarabine in Newly Diagnosed Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. Am J Hematol 93(1):91-99, 2018. e-Pub 2017. PMID: 29047158.
204. Roboz GJ, Kantarjian HM, Yee KWL, Kropf PL, O'Connell CL, Griffiths EA, Stock W, Daver NG, Jabbour E, Ritchie EK, Walsh KJ, Rizzieri D, Lunin SD, Curio T, Chung W, Hao Y, Lowder JN, Azab M, Issa JJ. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer 124(2):325-334, 2018. e-Pub 2017. PMID: 29211308.
205. Masarova L, Kantarjian H, Ravandi F, Sharma P, Garcia-Manero G, Daver NG. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice. Adv Exp Med Biol 995:97-116, 2018. PMID: 30539507.
206. Jain N, Lu X, Daver NG, Thakral B, Wang SA, Konoplev S, Patel K, Kanagal-Shamanna R, Valentine M, Tang G, Pemmaraju N, Jorgensen J, Kebriaei P, Nunez CA, Wierda W, Jabbour E, Roberts KG, Mullighan CG, Kantarjian H, Konopleva M. Concurrent diagnosis of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica 102(12):e514-e517, 2017. e-Pub 2017. PMID: 28860345.
207. Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver NG, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia T. Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience. Am J Hematol 92(12):1295-1302, 2017. e-Pub 2017. PMID: 28850699.
208. Wang W, Routbort MJ, Tang Z, Ok CY, Patel KP, Naval Daver, Garcia-Manero G, Medeiros LJ, Wang SA. Characterization of TP53 Mutations in Low-Grade Myelodysplastic Syndromes and Myelodysplastic Syndromes with a Non-Complex Karyotype. Eur J Haematol 99(6):536-543, 2017. e-Pub 2017. PMID: 28926144.
209. Assi R, Kantarjian H, Short NJ, Daver NG, Takahashi K, Garcia-Manero G, DiNardo C, Burger J, Cortes J, Jain N, Wierda W, Chamoun S, Konopleva M, Jabbour E. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk 17(12):897-901, 2017. e-Pub 2017. PMID: 28927784.
210. Daver NG Kontoyiannis DP. Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesis. Lancet Oncol 18(12):1571-1573, 2017. PMID: 29208429.
211. Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer 123(22):4430-4439, 2017. e-Pub 2017. PMID: 28708931.
212. Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer 123(22):4391-4402, 2017. e-Pub 2017. PMID: 28743165.
213. Daver NG, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk MDS. Haematologica 102(10):1709-1717, 2017. e-Pub 2017. PMID: 28729302.
214. Masarova L, Verstovsek S, Kantarjian H, Daver NG. Immunotherapy based approaches in myelofibrosis. Expert Rev Hematol 10(10):903-914, 2017. e-Pub 2017. PMID: 28799436.
215. Ragon BK,Daver NG, Garcia-Manero G, Ravandi F, Cortes J, Kadia T, Oran B, Ohanian M, Ferrajoli A, Pemmaraju N, Kantarjian HM, Borthakur G. Minimal Residual Disease Eradication with Epigenetic Therapy in Core Binding Factor Acute Myeloid Leukemia. Am J Hematol 92(9):845-850, 2017. e-Pub 2017. PMID: 28494506.
216. Daver NG, McClain K, Allen CE, Parikh SA, Otrock Z, Rojas-Hernandez C, Blechacz B, Wang S, Minkov M, Jordan MB, La Rosée P, Kantarjian HM. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer 123(17):3229-3240, 2017. e-Pub 2017. PMID: 28621800.
217. Mirandola L, Pedretti E, Figueroa JA, Chiaramonte R, Colombo M, Chapman C, Grizzi F, Patrinicola F, Kast WM, Nguyen DD, Rahman RL, Daver NG, Ruvolo P, Post SM, Bresalier RS, Chiriva-Internati M. Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy. Oncotarget 8(43):74378-74390, 2017. e-Pub 2017. PMID: 29088794.
218. Masarova L, Bose P, Naval Daver, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res 59:110-116, 2017. e-Pub 2017. PMID: 28601551.
219. Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver NG, Cortes J, Kantarjian H, Verstovsek S. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood 130(9):1125-1131, 2017. e-Pub 2017. PMID: 28674026.
220. Daver NG, Kantarjian H. FLT3 inhibition in acute myeloid leukaemia. Lancet Oncol 18(8):988-989, 2017. e-Pub 2017. PMID: 28759368.
221. Boddu P, Kantarjian H, Borthakur G, Kadia T, Daver NG, Pierce S, Andreeff M, Ravandi F, Cortes J, Kornblau SM. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Adv 1(19):1546-1550, 2017. e-Pub 2017. PMID: 29296796.
222. Otrock ZK, Daver NG, Kantarjian HM, Eby CS. Diagnostic Challenges of Hemophagocytic Lymphohistiocytosis. Clin Lymphoma Myeloma Leuk 17S:S105-S110, 2017. PMID: 28760295.
223. Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver NG, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv 1(17):1312-1323, 2017. e-Pub 2017. PMID: 29296774.
224. Shah AR, Muzzafar T, Assi R, Schellingerhout D, Estrov Z, Tamamyan G, Kantarjian H, Daver NG. Hemophagocytic lymphohistiocytosis in adults: An under recognized entity. BBA Clin 7:36-40, 2017. e-Pub 2016. PMID: 28070498.
225. Strati P, Masarova L, Bose P, Naval Daver, Pemmaraju N, Verstovsek S. Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. Leuk Res 57:85-88, 2017. e-Pub 2017. PMID: 28324773.
226. Hust MA, Blechacz BRA, Bonilla DL, Daver NG, Rojas-Hernandez CM. Adult cancer-related hemophagocytic lymphohistiocytosis - a challenging diagnosis: a case report. J Med Case Rep 11(1):172, 2017. e-Pub 2017. PMID: 28651636.
227. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver NG, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. Greater than one TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood 129(18):2584-2587, 2017. e-Pub 2017. PMID: 28246192.
228. Jabbour E, Daver NG, Short NJ, Huang X, Chen HC, Maiti A, Ravandi F, Cortes J, Abi Aad S, Garcia-Manero G, Estrov Z, Kadia T, O'Brien S, Dabaja B, Bueso-Ramos C, Strati P, Bivins C, Pierce S, Kantarjian H. Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol. e-Pub 2017. PMID: 28556489.
229. Naqvi K, Daver NG, Pemmaraju N, Bose P, Garcia-Manero G, Cortes J, Kantarjian HM, Verstovsek S. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leuk Lymphoma 58(4):1-6, 2017. e-Pub 2016. PMID: 27494751.
230. Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver NG, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO. Relapse Risk and Survival in Patients with FLT3 Acute Myeloid Leukemia Undergoing Stem Cell Transplantation. Am J Hematol 92(4):331-337, 2017. e-Pub 2017. PMID: 28052408.
231. Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, DiNardo C, Daver NG, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of Achievement of Complete Cytogenetic Response on Outcome in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents. Am J Hematol 92(4):351-358, 2017. e-Pub 2017. PMID: 28076892.
232. Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol 92(3):238-243, 2017. e-Pub 2017. PMID: 28006851.
233. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver NG, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 129(10):1275-1283, 2017. e-Pub 2016. PMID: 28003274.
234. Assi R, Verstovsek S, Naval Daver. 'Janus kinase-ing' up the treatment of primary myelofibrosis: building better combination strategies. Curr Opin Hematol 24(2):115-124, 2017. e-Pub 2017. PMID: 28072602.
235. Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver NG, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer 123(3):426-435, 2017. e-Pub 2016. PMID: 27657543.
236. Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver NG, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer 123(3):459-467, 2017. e-Pub 2016. PMID: 27696391.
237. Jabbour E, Faderl S, Sasaki K, Kadia T, Daver NG, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer 123(4):629-637, 2017. e-Pub 2016. PMID: 27741352.
238. Pinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, Naval Daver, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya-Matsuoka C, Woodman K, Dinardo C, Jain N, Kadia TM, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS. Dorsal Column Myelopathy after Intrathecal Chemotherapy for Leukemia. Am J Hematol 92(2):155-160, 2017. e-Pub 2016. PMID: 27874212.
239. Tamamyan G, Kadia T, Ravandi F, Borthakur G, Cortes J, Jabbour E, Daver NG, Ohanian M, Kantarjian H, Konopleva M. Frontline treatment of acute myeloid leukemia in adults. Crit Rev Oncol Hematol 110:20-34, 2017. e-Pub 2016. PMID: 28109402.
240. Daver NG, Kantarjian H. Malignancy-associated haemophagocytic lymphohistiocytosis in adults. Lancet Oncol 18(2):169-171, 2017. PMID: 28214404.
241. Galloway-Peña JR, Smith DP, Sahasrabhojane P, Wadsworth WD, Fellman BM, Ajami NJ, Shpall EJ, Daver NG, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA. Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients. Genome Med 9(1):21, 2017. e-Pub 2017. PMID: 28245856.
242. Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver NG. Buparlisib, a PI3K Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase I Trial of Patients with Advanced Leukemias. Am J Hematol 92(1):7-11, 2017. e-Pub 2016. PMID: 27673440.
243. Masarova L, Kantarjian H, Garcia-Manero G, Ravandi F, Sharma P, Daver NG. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. Adv Exp Med Biol 995:73-95, 2017. PMID: 28321813.
244. Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer 122(23):3650-3656, 2016. e-Pub 2016. PMID: 27479888.
245. Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver NG, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer 122(21):3336-3343, 2016. e-Pub 2016. PMID: 27509035.
246. Sasaki K, Jabbour E, Cortes J, Kadia T, Garcia-Manero G, Borthakur G, Jain P, Pierce S, Daver NG, Takahashi K, O'Brien S, Kantarjian H, Ravandi F. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clin Lymphoma Myeloma Leuk 16(11):616-624, 2016. e-Pub 2016. PMID: 27601000.
247. Alatrash G, Daver NG, Mittendorf EA. Targeting Immune Checkpoints in Hematologic Malignancies. Pharmacol Rev 68(4):1014-1025, 2016. PMID: 27664133.
248. Tamamyan GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, Konopleva MY, Garcia-Manero G, Benton CB, Chihara D, Rytting ME, Wang S, Abdelall W, Konoplev SN, Daver NG. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer 122(18):2857-66, 2016. e-Pub 2016. PMID: 27244347.
249. Nazha A, Khoury JD, Verstovsek S, Daver NG. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?. Crit Rev Oncol Hematol 105:112-7, 2016. e-Pub 2016. PMID: 27401783.
250. Daver NG, Konopleva M. Cotargeting BCL-2 and BCL-XL for maximal efficacy in ALL. Blood 128(10):1316-7, 2016. PMID: 27609539.
251. Khan M, Sarfraz M, Daver NG. Myelodysplastic/myeloproliferative neoplasms: a disease in need of recognition. Future Oncol. e-Pub 2016. PMID: 27676208.
252. Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver NG, Jain P, Satta T, Pierce S, Rios MB, Cortes JE. Frontline therapy with high-dose imatinib vs. 2nd generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - A propensity score analysis. Haematologica 101(8):e324-7, 2016. e-Pub 2016. PMID: 27175025.
253. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. Final results of a single institution experience with a pediatric-based regimen, the augmented berlin-frankfurt-münster (ABFM), in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL), and comparison to the hyper-CVAD regimen. Am J Hematol 91(8):819-23, 2016. e-Pub 2016. PMID: 27178680.
254. Galloway-Peña JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, Chemaly RF, Marsh L, Ghantoji SS, Pemmaraju N, Garcia-Manero G, Rezvani K, Alousi AM, Wargo JA, Shpall EJ, Futreal PA, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer 122(14):2186-96, 2016. e-Pub 2016. PMID: 27142181.
255. Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreeff M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. e-Pub 2016. PMID: 27463065.
256. Jain P, Tang G, Huh YO, Yin CC, Zuo Z, Pemmaraju N, Estrov Z, Daver NG. Philadelphia - positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation. Am J Hematol 91(6):647-8, 2016. e-Pub 2016. PMID: 26799924.
257. Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver NG, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol 91(4):385-9, 2016. e-Pub 2016. PMID: 26800008.
258. Vitale C, Jabbour E, Lu X, Yabe M, Kanagal Shamanna R, Daver NG, Pemmaraju N, Bueso-Ramos CE, Takahashi K. Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. Am J Hematol 91(4):E274-6, 2016. e-Pub 2016. PMID: 26798971.
259. Daver NG, Ravandi F. Enhancing cytotoxicity of immunotoxins in AML. Blood 127(23):2787-8, 2016. PMID: 27282944.
260. Ouyang J, Goswami M, Peng J, Zuo Z, Daver NG, Borthakur G, Tang G, Medeiros LJ, Jorgensen JL, Ravandi F, Wang SA. Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. Am J Clin Pathol 145(6):769-77, 2016. e-Pub 2016. PMID: 27298396.
261. Daver NG, Cortes J, Kantarjian H, Ravandi F. Acute myeloid leukemia: advancing clinical trials and promising therapeutics. Expert Rev Hematol 9(5):433-45, 2016. e-Pub 2016. PMID: 26910051.
262. Jain P, Tang G, Konoplev SN, Kanagal-Shamanna R, Wang SA, Pemmaraju N, Daver NG, Estrov Z. Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations. Am J Hematol 91(3):354-5, 2016. e-Pub 2016. PMID: 26437693.
263. Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver NG, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Impact of BCR-ABL transcript type on response and survival in patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 127(10):1269-75, 2016. e-Pub 2016. PMID: 26729897.
264. Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, Kadia T, Andreff M, Konopleva M, DiNardo C, Daver NG, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget 7(12):14172-87, 2016. e-Pub 2016. PMID: 26871476.
265. Sasaki K, Lahoti A, Jabbour E, Jain P, Pierce S, Borthakur G, Daver NG, Kadia T, Pemmaraju N, Ferrajoli A, O'Brien S, Kantarjian H, Cortes J. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clin Lymphoma Myeloma Leuk 16(3):152-62, 2016. e-Pub 2015. PMID: 26796981.
266. Daver NG, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Verstovsek S, Kadia T, Dinardo C, Pierce S, Huang X, Pemmaraju N, Diaz-Pines-Mateo M, Cortes J, Borthakur G. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia 30(2):268-73, 2016. e-Pub 2015. PMID: 26365212.
267. Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Takahashi K, Pemmaraju N, Daver NG, Pierce SA, O'Brien SM, Cortes JE. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer 122(2):238-48, 2016. e-Pub 2015. PMID: 26479889.
268. Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour EJ, Ravandi F, Daver NG, Luthra R, Kantarjian H, Garcia-Manero G. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res 39(12):1367-74, 2015. e-Pub 2015. PMID: 26547258.
269. Daver NG, Konopleva M. Sorafenib and novel multikinase inhibitors in AML. Lancet Oncol 16(16):1582-3, 2015. e-Pub 2015. PMID: 26549588.
270. Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver NG, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol 16(15):1547-55, 2015. e-Pub 2015. PMID: 26432046.
271. Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver NG, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JE. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol 90(11):1065-70, 2015. e-Pub 2015. PMID: 26299958.
272. Nazha A, Khoury JD, Rampal RK, Daver NG. Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications. Oncologist 20(10):1154-60, 2015. e-Pub 2015. PMID: 26304912.
273. Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Pierce SR, Newberry KJ, Daver NG, Verstovsek S. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res 39(9):950-6, 2015. e-Pub 2015. PMID: 26183878.
274. Badar T, Shetty A, Bueso-Ramos C, Cortes J, Konopleva M, Borthakur G, Pierce S, Huang X, Chen HC, Kadia T, Daver NG, Dinardo C, O'Brien S, Garcia-Manero G, Kantarjian H, Ravandi F. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. Am J Hematol 90(9):769-73, 2015. e-Pub 2015. PMID: 26017166.
275. Issa JP, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver NG, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol 16(9):1099-110, 2015. e-Pub 2015. PMID: 26296954.
276. Jain P, Kantarjian H, Jabbour E, Gonzalez GN, Borthakur G, Pemmaraju N, Daver NG, Gachimova E, Ferrajoli A, Kornblau S, Ravandi F, O'Brien S, Cortes J. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol 2(9):e376-e383, 2015. PMID: 26436130.
277. Kadia T, Kantarjian H, Garcia-Manero G, Borthakur G, Wang X, Patel K, Jabbour E, Brandt M, Daver NG, Pemmaraju N, Pierce S, Cortes J, Ravandi F. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol 170(4):590-3, 2015. e-Pub 2015. PMID: 25716073.
278. Daver NG, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S. Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. Haematologica 100(8):1058-63, 2015. e-Pub 2015. PMID: 26088933.
279. Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver NG, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica 100(7):927-34, 2015. e-Pub 2015. PMID: 25682597.
280. DiNardo CD, Jabbour E, Ravandi F, Takahashi K, Daver NG, Routbort M, Patel KP, Brandt M, Pierce S, Kantarjian H, Garcia-Manero G. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia. e-Pub 2015. PMID: 26228814.
281. Gowin K, Verstovsek S, Daver NG, Pemmaraju N, Valdez R, Kosiorek H, Dueck A, Mesa R. Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis. Leuk Res 39(7):684-8, 2015. e-Pub 2015. PMID: 25922307.
282. Kazmi SM, Pemmaraju N, Patel KP, Cohen PR, Daver NG, Tran KM, Ravandi F, Duvic M, Garcia-Manero G, Pierce S, Nazha A, Borthakur G, Kantarjian H, Cortes J. Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(6):358-63, 2015. e-Pub 2014. PMID: 25630528.
283. Daver NG, Boumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, Kawedia JD, Basnett J, Culotta KS, Zeng Z, Lu H, Richie MA, Garris R, Xiao L, Liu W, Baggerly KA, Jabbour E, O'Brien S, Burger J, Bendall LJ, Thomas D, Konopleva M. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed / Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res 21(12):2704-14, 2015. e-Pub 2015. PMID: 25724525.
284. Ouyang J, Goswami M, Tang G, Peng J, Ravandi F, Daver NG, Routbort M, Konoplev S, Lin P, Medeiros LJ, Jorgensen JL, Wang SA. The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia. Am J Hematol 90(6):504-10, 2015. e-Pub 2015. PMID: 25732229.
285. Eghtedar A, Rodriguez I, Kantarjian H, O'Brien S, Daver NG, Garcia-Manero G, Ferrajoli A, Kadia T, Pierce S, Cortes J, Ravandi F. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. Leuk Lymphoma 56(5):1-4, 2015. e-Pub 2014. PMID: 25120050.
286. Daver NG, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Haematologica 100(5):653-61, 2015. e-Pub 2015. PMID: 25682595.
287. Daver NG, Cortes J, Ravandi F, Patel KP, Burger JA, Konopleva M, Kantarjian H. Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood 125(21):3236-45, 2015. e-Pub 2015. PMID: 25795921.
288. Sasaki K, Strom SS, O'Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver NG, Jain P, Pierce S, Kantarjian H, Cortes JE. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2(5):e186-93, 2015. e-Pub 2015. PMID: 26688093.
289. Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver NG, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Phase I/II Trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol 90(4):276-81, 2015. e-Pub 2015. PMID: 25530214.
290. Cachia D, Kamiya-Matsuoka C, Pinnix CC, Chi L, Kantarjian HM, Cortes JE, Daver NG, Woodman K. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol 122(2):391-8, 2015. e-Pub 2015. PMID: 25666482.
291. Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver NG, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: A Report on Behalf of the MDS Clinical Research Consortium. Cancer 121(6):876-82, 2015. e-Pub 2014. PMID: 25410759.
292. Daver NG, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi F. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol 168(5):646-53, 2015. e-Pub 2014. PMID: 25312977.
293. Jabbour E, Garcia-Manero G, Cornelison AM, Cortes JE, Ravandi F, Daver NG, Kadia T, Teng A, Kantarjian H. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leuk Lymphoma 56(2):390-4, 2015. e-Pub 2014. PMID: 24844364.
294. Daver NG, Verstovsek S. Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis. Leuk Lymphoma 56(2):279-80, 2015. e-Pub 2014. PMID: 24913500.
295. Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver NG, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 15(2):110-4, 2015. e-Pub 2014. PMID: 25107338.
296. Kadia TM, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, Daver NG, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur G. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol 90(2):120-4, 2015. e-Pub 2014. PMID: 25368968.
297. Pemmaraju N, Sasaki K, Johnson D, Daver NG, Afshar-Kharghan V, Chen M, Ahmed S, Colen RR, Kwon M, Huh Y, Borthakur G. Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature. Front Oncol 5:29, 2015. e-Pub 2015. PMID: 25717439.
298. Daver NG, Cortes J. The changing face of acute myeloid leukemia therapeutics in the elderly population. South Asian J Cancer 4(1):1-2, 2015. PMID: 25839008.
299. DiNardo CD, Daver NG, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol 2(1):e12-20, 2015. e-Pub 2014. PMID: 26687423.
300. Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer 120(23):3660-8, 2014. e-Pub 2014. PMID: 25042398.
301. Quintás-Cardama A,Daver NG , Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 14(5):401-10, 2014. e-Pub 2014. PMID: 24875590.
302. Strati P, Pemmaraju N, Estrov Z, Cardenas-Turanzas M, Pierce S, Newberry KJ, Daver NG, Cortes J, Kantarjian H, Verstovsek S. Clinical significance of microcytosis in patients with primary myelofibrosis. Leuk Res 38(10):1212-6, 2014. e-Pub 2014. PMID: 25217891.
303. Daver NG, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res 38(9):1126-9, 2014. e-Pub 2014. PMID: 25047979.
304. Geethakumari PR, Hoffmann MS, Pemmaraju N, Hu S, Jorgensen JL, O'Brien S, Daver NG. Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge. Clin Lymphoma Myeloma Leuk 14(4):e115-8, 2014. e-Pub 2014. PMID: 24589157.
305. Shah DR, Daver NG, Borthakur G, Hirsch-Ginsberg C, Oo TH. Pernicious anemia with spuriously normal vitamin B12 level might be misdiagnosed as myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk 14(4):e141-3, 2014. e-Pub 2014. PMID: 24630920.
306. Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver NG, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma 55(6):1337-44, 2014. e-Pub 2013. PMID: 24004182.
307. Daver NG, Naqvi K, Jabbour E, Kadia T, DiNardo C, Cardenas-Turanzas M, Pierce S, Nguyen KT, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. Am J Hematol 89(5):509-16, 2014. e-Pub 2014. PMID: 24458781.
308. Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver NG, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia 28(4):973-5, 2014. e-Pub 2013. PMID: 24157581.
309. Jabbour E, Daver NG, Champlin R, Mathisen M, Oran B, Ciurea S, Khouri I, Cornelison AM, Ghanem H, Cardenas-Turanzas M, Popat U, Ravandi F, Giralt S, Garcia-Manero G, Cortes J, Kantarjian H, de Lima M. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol 89(4):395-8, 2014. e-Pub 2014. PMID: 24375514.
310. Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver NG, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur G. Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. Clin Lymphoma Myeloma Leuk 14(2):163-71, 2014. e-Pub 2014. PMID: 24461514.
311. DiNardo CD, Daver NG, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia 28(4):958-61, 2014. e-Pub 2014. PMID: 24492324.
312. Ghanem H, Garcia-Manero G, Faderl S, Ravandi F, Cortes J, Katragadda L, O'Brien S, Daver NG, Pierce S, Kadia T, Kantarjian H, Jabbour E. Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. Ther Adv Hematol 5(2):29-34, 2014. PMID: 24688752.
313. Pemmaraju N, Chang E, Daver NG, Patel K, Jorgensen J, Sabloff B, Verstovsek S, Borthakur G. Extramedullary acute myeloid leukemia: leukemic pleural effusion, case report and review of the literature. Front Oncol 4:130, 2014. e-Pub 2014. PMID: 24918086.
314. Sasaki K, Pemmaraju N, Westin JR, Wang WL, Khoury JD, Podoloff DA, Moon B, Daver NG, Borthakur G. A single case of rosai-dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine. Front Oncol 4:297, 2014. e-Pub 2014. PMID: 25401088.
315. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver NG, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients 60 years with newly diagnosed acute myeloid leukemia. Am J Hematol 88(11):961-6, 2013. e-Pub 2013. PMID: 23877926.
316. Daver NG, Shastri A, Kadia T, Quintas-Cardama A, Jabbour E, Konopleva M, O'Brien S, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res 37(11):1440-4, 2013. e-Pub 2013. PMID: 23890523.
317. Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver NG, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia 27(10):2081-3, 2013. e-Pub 2013. PMID: 23774633.
318. Daver NG, Vega-Ruiz A, Kantarjian HM, Estrov Z, Ferrajoli A, Kornblau S, Verstovsek S, Garcia-Manero G, Cortes JE. A phase II Open-label Study of the Intravenous Administration of Homoharringtonine in the treatment of Myelodysplastic syndrome. Eur J Cancer Care (Engl) 22(5):605-11, 2013. e-Pub 2013. PMID: 23701251.
319. Strati P, Daver NG, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13 Suppl 2:S276-81, 2013. e-Pub 2013. PMID: 23969309.
320. Daver NG, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quintás-Cardama A. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk 13(4):435-40, 2013. e-Pub 2013. PMID: 23763915.
321. Daver NG, O'Brien S. Novel Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia - A Focus on Emerging Monoclonal Antibodies. Curr Hematol Malig Rep 8(2):123-31, 2013. e-Pub 2013. PMID: 23539383.
322. Bhamidipati PK, Jabbour E, Konoplev S, Estrov Z, Cortes J, Daver NG. Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine. Clin Lymphoma Myeloma Leuk 13(3):342-6, 2013. e-Pub 2012. PMID: 23246163.
323. Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver NG, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 121(23):4655-62, 2013. e-Pub 2013. PMID: 23613521.
324. Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver NG, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia 27(4):836-42, 2013. e-Pub 2012. PMID: 23135353.
325. Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver NG, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol 88(3):198-200, 2013. e-Pub 2013. PMID: 23345254.
326. Daver NG, Nazha A, Kantarjian HM, Haltom R, Ravandi F. Treatment of hairy cell leukemia during pregnancy: Are purine analogues and rituximab viable therapeutic options. Clin Lymphoma Myeloma Leuk 13(1):86-9, 2013. e-Pub 2012. PMID: 22981963.
327. Borthakur G, Rosenblum MG, Talpaz M, Daver NG, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE. Phase 1 Study of Anti-CD33 Immunotoxin HUM-195/rGEL in Patients with Advanced Myeloid Malignancies. Haematologica 98(2):217-21, 2013. e-Pub 2012. PMID: 22875630.
328. Lee HJ, Daver NG, Kantarjian HM, Verstovsek S, Ravandi F. The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia. Clin Cancer Res 19(2):327-35, 2013. e-Pub 2012. PMID: 23209034.
329. Daver NG, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol 88(1):56-9, 2013. e-Pub 2012. PMID: 23115106.
330. Nazha A, Cortes J, Faderl S, Pierce S, Daver NG, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating mutations of the FMS-like tyrosine kinase-3 internaltandem duplication (FLT3-ITD) at complete response and relapsein patients with acute myeloid leukemia. Haematologica 97(8):1242-5, 2012. e-Pub 2012. PMID: 22532519.
331. Shastri A, Daver NG, Hayes TG. Primary gastric chorioadenocarcinoma: a needle in a haystack. Rare Tumors 3(2):e19, 2011. PMID: 21769318.
332. Tanaka MF, Daver NG,Rice L. Romiplostim: Therapeutic Value in Chronic Immune Thrombocytopenic Purpura. Clinical Medical Insights: Therapeutics(2):499-511, 2010.
333. Livorsi DJ, Daver NG, Atmar RL, Shelburne SA, White AC, Musher DM. Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA. J Infect 57(2):128-31, 2008. e-Pub 2008. PMID: 18562009.
334. Daver NG, Shelburne SA, Atmar RL, Giordano TP, Stager CE, Reitman CA, White AC. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. The Journal of Infection 54(6):539-44, 2007. e-Pub 2007. PMID: 17198732.
335. del la Garza Y, Graviss EA, Daver NG, Gambarin KJ, Shandera WX, Schantz PM, White AC. Epidemiology of neurocysticercosis in Houston, Texas. American Journal Tropical Medicine and Hygiene 73(4):766-70, 2005. PMID: 16222023.
336. Daver GB, Bakhshi GD, Patil A, Ellur S, Jain M, Daver N. Bifid liver in a patient with diaphragmatic hernia. Indian J Gastroenterol 24(1):27-8, 2005. PMID: 15778526.
337. Joshi SR, Butala N, Patwardhan MR, Daver NG, Kelkar D. Low cost anti-retroviral options: chloroquine based ARV regimen combined with hydroxyurea and lamivudine: a new economical triple therapy. J Assoc Physicians India 52(1):597- 598, 2004. PMID: 15645995.
338. Chen Y, Kantarjian H, Pierce S, Faderl S, O' Brien S, Qian W, Abruzzo L, De Lima M, Kebriaaei P, Jabbour E, Daver NG, Kadia T, Garcia-Manero G, Cortes JE, Ravandi F. Prognostic Significance of 11q23 Cytogenetic Abnormalities in Adult Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation. Blood.
339. Bhamidipati P, Jabbour E, Konoplev S, Estrov Z, Cortes JE, Daver NG. EBV Induced CD30 Positive Diffuse Large B-Cell Lymphoma in a Mixed Phenotypic Leukemia patient treated with Clofarabine. Clinical Lymphoma, Myeloma & Leukemia.
340. Shastri A, Daver NG, Hayes T. A rare case of Gastric Chorio - adenocarcinoma. Rare tumors 2011.

Invited Articles

1. Daver NG, Cortes J. Molecular targeted therapy in Acute Myeloid Leukemia. Hematology 17 Suppl 1:S59-62, 2012. PMID: 22507781.

Other Articles

1. Daver NG New therapeutic options in Adult ALL. Leukemia Insights 16(2), 2011.
2. Daver NG, Jabbour E Salvage Treatment Options in AML. Leukemia Insights 16(2), 2011.

Abstracts

1. Pemmaraju N, Marconi G, Todisco E, Montesinos P, Lane AA, Sweet K, Wang ES, Deconinck E, Rizzieri DA, Walter RB, Aribi A, Lebon D, Levy MY, Mazzarella L, Martinelli G, Gigli G, Erba HP, Acuña-Cruz E, Konopleva M, Kantarjian H, Sloss CM, Wang J, Malcolm KE, Zweidler-McKay PA, DeAngelo DJ, Daver NG. A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood 138(Supp. 1), 2021.
2. Daver NG, Lee KH, Jung CW, Yoon SS, Arellano ML, Yoon J, Lee N, Kim H, Lee J, Jonas BA, Baek S. First in Human (FIH) FLT3 and SYK Inhibitor HM43239 Shows Single Agent Activity in Patients (pts) with Relapsed or Refractory (R/R) FLT3 Mutated and Wild-Type Acute Myeloid Leukemia (AML). Blood 138(Supp. 1), 2021.
3. Daver NG, Harry P. Erba, Nikolaos Papadantonakis, Daniel J. DeAngelo, Eunice S. Wang, Marina Y. Konopleva, Callum M. Sloss, Kerry Culm-Merdek, Patrick A. Zweidler-McKay, and Hagop M. Kantarjian. A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies. Blood 132(27), 2018.
4. Daver NG, Marina Kremyanskaya, Casey O'Connell, Kim-Hien Dao, Stephen T Oh, Aaron T. Gerds, Srdan Verstovsek, Sue Erickson-Viitanen, Feng Zhou, Albert Assad, and Abdulraheem Yacoub. A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis. Blood 132(353), 2018.
5. Lucia Masarova, Srdan Verstovsek, Jorge E. Cortes, Naveen Pemmaraju, Prithviraj Bose, Maro N. Ohanian, Lingsha Zhou, Sherry A. Pierce, Romany Gergis, Gautam Borthakur, Zeev E. Estrov, Guillermo Garcia-Manero, Hagop M. Kantarjian, and Daver NG. Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis. Blood 132(352), 2018.
6. Daver NG, Guillermo Garcia-Manero, Sreyashi Basu, Jorge E. Cortes, Farhad Ravandi, Tapan M. Kadia, Marina Y. Konopleva, Elias J. Jabbour, Courtney D. DiNardo, Rita Assi, Sherry A. Pierce, Yesid Alvarado, Zeev E. Estrov, Naveen Pemmaraju, Koichi Takahashi, Jing Ning, Graciela M. Nogueras González, Steven M. Kornblau, Mansour Alfayez, Jairo Matthews, Wilmer Flores, Jorge Blando, James P Allison, Padmanee Sharma, and Hagop M. Kantarjian. Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study. Blood 132(906), 2018.
7. Daver NG, Daniel A Pollyea, Jacqueline S. Garcia, Brian A. Jonas, Karen W.L. Yee, Pierre Fenaux, Sarit Assouline, Norbert Vey, Rebecca Olin, Gail J. Roboz, Agostino Tafuri, Giuseppe Visani, Whitney Kirschbrown, Cherie Green, Connie Ma, Monique Dail, Jue Wang, Marion G Ott, Mehrdad Mobasher, Patrick Phuong, Wan-Jen Hong, Marina Y. Konopleva, and Michael Andreeff. Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study. Blood 132(767), 2018.
8. Mansour Alfayez, Hagop M. Kantarjian, Farhad Ravandi, Marina Y. Konopleva, Guillermo Garcia-Manero, Tapan M. Kadia, Elias J. Jabbour, Gautam Borthakur, Courtney D. DiNardo, Zeev E. Estrov, Naveen Pemmaraju, Sherry A. Pierce, Musa E. Yilmaz, Nicholas J Short, Koichi Takahashi, Rita Assi, Michael Andreeff, Jorge E. Cortes, and Daver NG. Outcomes with Subsequent FLT3-Inhibitor (FLT3i) Based Therapies in FLT3-Mutated (mu) Patients (pts) Refractory/Relapsed (R/R) to One or More Prior FLT3 Inhibitor Based Therapies: A Single Center Experience. Blood 132(663), 2018.
9. Betul Oran, Guillermo Garcia-Manero, Rima M. Saliba, Gheath Alatrash, Elias J. Jabbour, Uday Popat, Farhad Ravandi, Tapan M. Kadia, Jorge E. Cortes, Amin M. Alousi, Marina Y. Konopleva, Courtney D. DiNardo, Katy Rezvani, Mansour Alfayez, Elizabeth J. Shpall, Padmanee Sharma, Richard E Champlin, Hagop M. Kantarjian, and Daver NG. Post Allogeneic Stem Cell Transplant (SCT) Cyclophosphamide Improves Progression Free Survival (PFS) in Pts with AML/MDS Treated with CTLA-4 or PD-1 Blockade Prior to SCT. Blood 132(483), 2018.
10. Koji Sasaki, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Koichi Takahashi, Marina Konopleva, Gautam Borthakur, Guillermo Garcia-Mareno, William Wierda, Naval Daver, Preetesh Jain, Toshihisa Satta, Sherry Pierce, Mary Beth Rios, Jorge E. Cortes. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis. Haematologica 101(8):e324-e327, 2016.
11. Naval Daver, Farhad Ravandi. Enhancing cytotoxicity of immunotoxins in AML. Blood 127(23):2787-2788, 2016.
12. Preetesh Jain, Hagop Kantarjian, Keyur P. Patel, Graciela Nogueras Gonzalez, Rajyalakshmi Luthra, Rashmi Kanagal Shamanna, Koji Sasaki, Elias Jabbour, Carlos Guillermo Romo, Tapan M. Kadia, Naveen Pemmaraju, Naval Daver, Gautam Borthakur, Zeev Estrov, Farhad Ravandi, Susan O’Brien, Jorge Cortes. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 127(10):1269-1275, 2016.
13. Courtney D. DiNardo, Naval Daver, Elias Jabbour, Tapan Kadia, Gautam Borthakur, Marina Konopleva, Naveen Pemmaraju, Hui Yang, Yue Wei, William G. Wierda, Carlos E. Bueso-Ramos, Keyur P. Patel, Jorge E. Cortes, Farhad Ravandi, Hagop Kantarjian, Guillermo Garcia-Manero. A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood 124(21):164, 2015.
14. Talha Badar, Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Jorge E Cortes, Naveen Pemmaraju, Sherry R Pierce, Naval Daver, Srdan Verstovsek. Therapeutic Benefit of Decitabine, a Hypomethylating Agent, in Patients with Myeloproliferative Neoplasm in Blastic Phase/Acute Myeloid Leukemia (MPN-AML), Accelerated Phase (MPN-AP), and DIPSS-Plus High Risk Primary Myelofibrosis (PMF). Blood 124(21):3186, 2015.
15. Ghayas c Issa, Hagop M Kantarjian, Elias Jabbour, Gautam Borthakur, Srdan Verstovsek, Sherry Pierce, William Wierda, Alessandra Ferrajoli, Guillermo Garcia-Manero, Tapan Kadia, Naval Daver, Naveen Pemmaraju, Farhad Ravandi, Sara Emogene DelaSala, Jorge E Cortes. Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia. Blood 126(23):823, 2015.
16. Naval Daver, Guillermo Garcia-Manero, Jorge E Cortes, Lingsha Zhou, Sherry Pierce, Naveen Pemmaraju, Elias Jabbour, Courtney DiNardo, Tapan Kadia, Gautam Borthakur, Farhad Ravandi, Marina Konopleva, Franklin Wynn, Stephanie Van Derbur, Zeev Estrov, Hagop Kantarjian, Srdan Verstovsek. 5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloprliferative Neoplasms (MDS/MPNs). Blood 126(23):823, 2015.
17. Naval Daver, Hagop Kantarjian, Guillermo Garcia-Manero, Elias Jabbour, Naveen Pemmaraju, Kenneth Vaughan, Sherry Pierce, Marina Konopleva, Tapan Kadia, Courtney DiNardo, Gautam Borthakur, Jorge E Cortes, Adam R Craig, Farhad Ravandi. Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). Blood 126(23):461, 2015.
18. Brittany Knick Ragon, Naval Daver, Guillermo Garcia-Manero, Maro Ohanian, Alessandra Ferrajoli, Naveen Pemmaraju, Hagop M Kantarjian, Gautam Borthakur. Fusion Transcript Reduction in Core Binding Factor Acute Myeloid Leukemia: Maintenance Strategy with Hypomethylating Agents. Blood 126(23):2604, 2015.
19. Lucia Masarova, Naval Daver, Naveen Pemmaraju, Prithviraj Bose, Sherry Pierce, Taghi Manshouri, Jorge E. Cortes, Hagop M Kantarjian, Srdan Verstovsek. Do Patients with Post-Essential Thrombocythemia and Post-Polycythemia Vera Differ from Patients with Primary Myelofibrosis. Blood 126(23):4069, 2015.
20. Mary Akosile, Sherry Pierce, Mark Brandt, Srdan Verstovsek, Gautam Borthakur, Hagop Kantarjian, Farhad Ravandi, William Wierda, Guillermo Garcia-Manero, Naval Daver, Tapan Kadia, Jan A. Burger, Naveen Pemmaraju, Elias Jabbour, Jorge E Cortes. Survival Impact of Patients (Pts) with Chronic Myeloid Leukemia (CML) Due to Failure from the Use of One or More Tyrosine Kinase Inhibitors (TKI). Blood 126(23):1587, 2015.
21. Naveen Pemmaraju, Hagop M Kantarjian, Jorge E Cortes, Madeleine Duvic, Joseph D Khoury, Keyur Patel, Naval Daver, Susan O'Brien, Sherry Pierce, Guillermo Garcia-Manero, Elias Jabbour, Nitin Jain, Stefan Faderl, Deborah Thomas, Arthur E Frankel, Muzaffar H Qazilbash, Marina Konopleva. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characterists and Patient Outcomes. Blood 126(23):3746, 2015.
22. Koichi Takahashi, Feng Wang, Seth Sahil, Jianhua Zhang, Curtis Gumbs, Ghayas C Issa, Christopher B Benton, Sherry Pierce, Elias Jabbour, Naval Daver, Tapan Kadia, Courtney DiNardo, Hagop M Kantarjian, Andrew Futreal, Guillermo Garcia-Manero. Presence of 4 or More Driver Mutations Predicts Poor Response to Hypomethylating Agent (HMA) Therapy and Poor Overall Survival in MDS. Blood 126(23):1663, 2015.
23. Punit L Jain, Koji Sasaki, Hagop Kantarjian, Farhad Ravandi, Jorge E Cortes, Guillermo Garcia-Manero, Prithviraj Bose, Naval Daver, Tapan Kadia, Srdan Verstovsek, Marina Konopleva, Nitin Jain, Guillermo Bravo Montalban, Sherry Pierce, Elias Jabbour. Outcome of Adult Patients with Philadelphia Negative B Cell Acute Lymphoblastic Leukemia after Frontline Therapy Failure. Blood 126(23):3718, 2015.
24. Shyamala C Navada, Lewis R Silverman, Katherine P Hearn, Rosalie Odchimar-Reissig, Erin P Demakos, Yesid Alvarado, Naval Daver, Courtney DiNardo, Marina Konopleva, Gautam Borthakur, Naveen Pemmaraju, Tapan Kadia, Pierre Fenaux, Steve Fruchtman, Nozar Azarnia, Guillermo Garcia-Manero. A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS). Blood 126(23):910, 2015.
25. Koichi Takahashi, Hagop M. Kantarjian, Keyur Patel, Carlos E Bueso-Ramos, Tapan Kadia, Elias Jabbour, Courtney DiNardo, Naval Daver, Sherry Pierce, Andrew Futreal, Guillermo Garcia-Manero. TP53 Mutated MDS Patients Respond Equally to Hypomethylating Agents but Have Significantly Shorter Response Duration Compared to Patients with Wild Type TP53. Blood 126(23):1681, 2015.
26. Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Nicholas J Short, Koji Sasaki, Mikkael A Sekeres, Rami S Komrokji, David P Steensma, Amy E DeZern, Gail J Roboz, Tapan Kadia, Gautam Borthakur, Courtney DiNardo, Darla Miller, Zeev Estrov, Naveen Pemmaraju, Naval Daver, Marina Konopleva, Jorge E Cortes, Hagop M Kantarjian, Elias Jabbour. Impact of Cytogenetic Abnormalties and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS). Blood 126(23):2877, 2015.
27. Weiguo Zhang, Jo Ishizawa, Hong Mu, Naval Daver, Vivian Ruvolo, Michael Andreff. Combinatorial Targeting of XPO1 and FLT3-ITD Exerts Synergistic Anti-Tumor Effects in FLT3-Mutated Acute Myeloid Leukemias. Blood 126(23):1266, 2015.
28. Yasmin Abaza, Hagop M Kantarjian, Gautam Borthakur, Naval Daver, Farhad Ravandi, Dai Chihara, Srdan Verstovsek, Jan A Burger, Zeev Estrov, Maro Ohanian, Elias Jabbour, Jorge E Cortes. An Open-label, Phase I Study of Dasatinib in Combination with Decitabine in Patients (Pts) with Accelerated or Blastic Phase Chronic Myeloid Leukemia (CML). Blood 126(23):1589, 2015.
29. Guillermo Montalban-Bravo, Hagop M Kantarjian, Punit L Jain, Guillermo Garcia-Manero, Farhad Ravandi, Jorge E Cortes, Naval Daver, Koichi Takahashi, Nitin Jain, Srdan Verstovsek, Tapan Kadia, Sherry Pierce, Elias Jabbour. Outcome of Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (ALL) and Isolated Central Nervous System (CNS) Relapse. Blood 126(23):2503, 2015.
30. Nicholas J Short, Guillermo Garcia-Manero, Guillermo Montalban Bravo, Koji Sasaki, Mikkael A Sekeres, Rami S Komrokji, David Steensma, AMy E DeZern, Gail Roboz, Tapan Kadia, Gautam Borthakur, Courtney DiNardo, Darl Miller, Zeev Estrov, Naveen Pemmaraji, Naval Daver, Srdan Verstovsek, Hagop Kantarjian, Elias Jabbour. Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate- 1 Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium. Blood 126(23):94, 2015.
31. Tapan Kadia, Jorge E Cortes, Farhad Ravandi, Guillermo Garcia-Manero, Michael Andreeff, Koichi Takahashi, Gautam Borthakur, Elias J Jabbour, Kapil N Bhalla, Marina Konopleva, Naval Daver, Courtney DiNardo, Prithviraj Bose, Keyur P Patel, Sherry Pierce, Hagop M Kantarjian. Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia. Blood 126(23):564, 2015.
32. Hagop Kantarjian, Elias Jabbour, Guillermo Garcia-Manero, Tapan Kadia, Courtney DiNardo, Naval Daver, Gautam Borthakur, Nitin Jain, Jane Waukau, Monica Kwari, Barry Douglas Anderson, Kenzo Lizuka, Cheng Jin, William Plunkett. Results of a Phase I/II Study of DFP- 10917, a Nucleoside Analog, Given By Continuous Infusion (CI) in Patients (pts) with Relapsed or Refractory Acute Leukemia. Blood 126(23):3804, 2015.
33. Gevorg Tamamyan, Gautam Borthakur, Jorge E Cortes, Farhad Ravandi, Elias Jabbour, Naval Daver, Naveen Pemmaraju, Maro Ohanian, Albert Kolomansky, Gabriele Todisco, Ce Shi, Sherry Pierce, S. Andrew Peng, Marina Konopleva, Hagop Kantarjian, Tapan Kadia. Prognostic Score for Adults with Acute Myeloid Leukemia in First Complete Remission. Blood 126(23):3850, 2015.
34. Jad Chahoud, Hagop M Kantarjian, Guillermo Garcia-Manero, Koji Sasaki, Tapan Kadia, Jorge E Cortes, Maria R Khouri, Farhad Ravandi, Jenny Dahl, Alessandra Ferrajoli, Jovitta Jacob, Naveen Pemmaraju, Naval Daver, Rebecca Garris, Elias Jabbour. Outcome of Patients with Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) after Failure of Inotuzumab Ozogamicin. Blood 126(23):1298, 2015.
35. Paul B Koller, Koji Sasaki, Farhad Ravandi, Guillermo Garcia-Manero, Susan O'Brien, Jorge E Cortes, Tapan Kadia, Gautam Borthakur, Naveen Pemmaraju, Naval Daver, Jad Chahoud, Allison Pike, Mark Brandt, Sherry Pierce, Hagop M Kantarjian, Elias Jabbour. Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase II Clinical Trial. Blood 126(23):2508, 2015.
36. Birendra KC, Hagop M Kantarjian, Guillermo Garcia-Manero, Naval Daver, Gautam Borthakur, Marina Konopleva, Michael Andreeff, Dai Chihara, Tapan Kadia, Prithviraj Bose, Zeev Estrov, Naveen Pemmaraju, Farhad Ravandi, Jorge E Cortes. Prognostic Significance of Somatic Mutations in Treatment of AML in Salvage Setting: A Retrospective Analysis. Blood 126(23):1313, 2015.
37. Lina Han, Qi Zhang, Ce Shi, Joel Leverson, Monique Dail, Darren C. Phillips, Jun Chen, Sha S Jin, Rodrigo Omar Jacamo, Naval Daver, Elias J Jabbour, Hagop M Kantarjian, Michael Andreeff, Deepak Sampath, Marina Konopleva. Concomitantly Targeting BCL-2 with Venetoclax (ABT-199/GDC-0199) and MAPK Signaling with Cobimetinib (GDC-0973) in Acute Myeloid Leukemia Models. Blood 126(23):2544, 2015.
38. Koji Sasaki, Paul B Koller, Hagop M Kantarjian, Deborah A Thomas, Maria R Khouri, Guillermo Garcia-Manero, Rebecca Garris, Jorge E Cortes, Heather Schroeder, Jad Chahoud, Tapan Kadia, Farhad Ravandi, Srdan Verstovsek, Naval Daver, Nitin Jain, Marina Konopleva, Susan O'Brien, Elias Jabbour. Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood 126(23):1295, 2015.
39. Preetesh Jain, Hagop M Kantarjian, Elias Jabbour, Zeev Estrov, Gautam Borthakur, Naveen Pemmaraju, Tapan Kadia, Naval Daver, Farhad Ravandi, Srdan Verstovsek, Susan O'Brien, Jorge E Cortes. Outcomes of Patients with Chronic Phase CML Who Discontinued Ponatinib in the Frontline Setting. Blood 126(23):1580, 2015.
40. Tapan Kadia, Jorge E Cortes, Elias Jabbour, Naval Daver, Naveen Pemmaraju, Farhad Ravandi, Nitin Jain, Srdan Verstovsek, Courtney DiNardo, Yesid Alvarado, Alessandra Ferrajoli, Jan A Burger, Guillermo Garcia-Manero, Maro Ohanian, Marina Konopleva, Zeev Estrov, William Wierda, Mark Brandt, Tina Fitch, Gautam Borthakur, Hagop Kantarjian. Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML). Blood 126(23):2541, 2015.
41. John Carl Pantetta, Sharyn D Baker, Hagop Kantarjian, Clinton Stewart, BLake Pond, Mehan Macaraeg, Tolu Makinde, Sheetal Vali, Naval Daver, Abhijit Ramachandran, Robert Collins, Jorge E Cortes. Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML. Blood 126(23):3695, 2015.
42. Farhad Ravandi, Jorgensin L Jeffrey, Elias J Jabbour, Gautam Borthakur, Tapan Kadia, Stefan Faderl, Sherry Pierce, Mark Brandt, Sa A Wang, Sergej Konoplev, Naval Daver, Naveen Pemmaraju, Guillermo Garcia-Manero, Michael Andreeff, Marina Konopleva, Jorge E Cortes, Hagop M Kantarjian. Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry Is a Strong Predictor of Outcome in Younger Patients with Acute Myeloid Leukemia. Blood 126(23):2579, 2015.
43. Farhad Ravandi, Jorge E Cortes, Guillermo Garcia-Manero, Elihu Estey, Gautam Borthakur, Elias J Jabbour, Stefan Faderl, Susan O'Brien, William Wierda, Sherry Pierce, Mark Brandt, Steven M Kornblau, Tapan Kadia, Naval Daver, Courtney DiNardo, Srdan Verstovsek, Alessandra Ferrajoli, Michael Andreeff, Marina Konopleva, Zeev Estrov, Maria Foudray, Hagop Kantarjian. Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoci Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin. Blood 126(23):3776, 2015.
44. Nicholas J Short, Hagop Kantarjian, Elias Jabbour, Susan O'Brien, Stefan Faderl, Jan A Burger, Rebecca Garris, Wei Qiao, Xuelin Huang, Nitin Jain, Marina Konopleva, Tapan Kadia, Naval Daver, Gautam Borthakur, Jorge E Cortes, Farhad Ravandi. Persistance of Cytogenetic Abnormalities at Complete Remission Is No Prognostic for Relapse-Free or Overall Survival in Adult Patients with Acute Lymphoblastic Leukemia. Blood 126(23):1416, 2015.
45. Daver NG, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Verstovsek S, Kadia T, DiNardo C, Pierce S, Huang X, Pemmaraju N, Diaz-Pines-Mateo M, Cortes J, Borthakur G.. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 2015. PMID: 26365212.
46. Naval Daver, Jorge Cortes, Kate Newberry, Elias Jabbour, Lingsha Zhou, Xuemei Wang, Sherry Pierce, Tapan Kadia, Koji Sasaki, Gautam Borthakur, Farhad Ravandi, Naveen Pemmaraju, Hagop Kantarjian, Srdan Verstovsek. Ruxolitinib in Combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica 100(8):1058-1063, 2015.
47. Marina Konopleva, Peter F. Thall, Cecilia Arana Yi, Gautam Borthakur, Andrew Coveler, Carlos Bueso-Ramos, Juliana Benito, Sergej Konoplev, Yongchuan Gu, Farhad Ravandi, Elias Jabbour, Stefan Faderl, Deborah Thomas, Jorge Cortes, Tapan Kadia, Steven Kornblau, Naval Daver, Naveen Pemmaraju, Hoang Q. Nguyen, Jennie Feliu, Hongbo Lu, Caimiao Wei, William R. Wilson, Teresa J. Melink, John C. Gutheil, Michael Andreeff, Elihu H. Estey, Hagop Kantarjian. Phase I/II Study of the Hypoxia-Activated Prodrg PR104 In Refractory/Relapsed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia. Haematologica 100(7):927-934, 2015.
48. Naval Daver, Marina Konopleva, Holbrook Edwin Kohrt, Jordan Scott Fridman, Dan Johnson, Juan C. Jaen, Hagop M. Kantarjian, Jorge E. Cortes. First-in-human stuty of FLX925, an orally administered FLT3/CDK4/DCK6 inhibitor, in subjects with relapsed or refractory acute myeloid leukemia (AML). 2015 ASCO Annual Meeting, 2015.
49. Naval Daver, Hagop M. Kantarjian, Sherry Pierce, Mark Brandt, Courtney Denton Dinardo, Naveen Pemmaraju, Kenneth Vaughan, Guillermo Garcia-Manero, Elias Jabbour, Gautam Borthakur, Tapan M. Kadia, Jorge E. Cortes, Adam Craig, Farhad Ravandi. Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). 2015 ASCO Annual Meeting, 2015.
50. Naval Daver, Marcos J.G. De Lima, Hagop Kantarjian, Farhad Ravandi, Mehmet Asim Bilen, Sherry Pierce, Issa F. Khouri, Stephan Joseph Dorkhom, Sergio Giralt, Guillermo Garcia-Manero, Aziz Nazha, Michael Mathisen, Naveen Pemmaraju, Jorge E. Cortes, Stefan Faderl, Elias Jabbour. Allogenic stem cell transplant (ASCT) as initial salvage for patients (pts) with acute myeloid leukemia (AML) refractory to high-dose cytarabine-based induction chemotherapy. 2015 ASCO Annual Meeting, 2015.
51. Naval Daver. First-in-human study of FLX925, an orally administered FLT3/CDK4/CDK6 inhibitor, in subjects with relapsed or refractory acute myeloid leukemia (AML). 2015 ASCO Annual Meeting, 2015.
52. Koji Sasaki, Hagop M. Kantarjian, Elias Jabbour, Farhad Ravandi, Koichi Takahashi, Marina Konopleva, Gautam Borthakur, Guillermo Garcia-Manero, William G. Wierda, Naval Daver, Preetesh Jain, Sherry Pierce, Mary Beth Rios, Jorge E. Cortes. Propensity score analysis: Frontline therapy with high-dose (HD) imatinib vs. 2nd generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in chronic phase. 2015 ASCO Annual Meeting, 2015.
53. Krisstina L. Gowin, Srdan Verstovsek, Naval Daver, Naveen Pemmaraju, Ricardo Valdez, Heidi Kosiorek, Amylou C. Dueck, Ruben A. Mesa. Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis. 2015 ASCO Annual Meeting, 2015.
54. Hagop M. Kantarjian, Elias Jabbour, Guillermo Garcia-Manero, Tapan M. Kadia, Courtney Denton Dinardo, Naval Daver, Gautam Borthakur, Nitin Jain, Jane Waukau, Monica Kwari, Barry Douglas Anderson, Kenzo Iizuka, Cheng Jin, William Plunkett. First report of a phase I/II study of DFP-10917, a nucleoside analog, given by continuous infusion (CI) in patients (pts) with relapsed or refractory acute leukemia. 2015 ASCO Annual Meeting, 2015.
55. Young Kwang Chae, Anastasios Dimou, Koichi Takahashi, Christopher Brent Benton, Elias Jabbour, Farhad Ravandi, Gautam Borthakur, Jorge E. Cortes, Tapan M. Kadia, Deborah A. Thomas, William G. Wierda, Naval Daver, Courtney Denton Dinardo, Hagop M. Kantarjian, Guillermo Garcia-Manero. Effect of vorinostat use on survival in patients with acute myeloid leukemia (AML) with FLT3 ITD mutations. 2015 ASCO Annual Meeting, 2015.
56. Talha Badar, Rajyalakshmi Luthra, Hagop M. Kantarjian, Elias Jabbour, Gautam Borthakur, Naval Guastad Daver, Xuelin Huang, Rajesh Singh, Brittany Alvarez, Tom Morrison, Jorge E. Cortes. New tool for monitoring molecular response in chronic myeloid leukemia. 2015 ASCO Annual Meeting, 2015.
57. Naval Daver, Deborah Thomas, Farhad Ravandi, Jorge Cortes, Rebecca Garris, Elias Jabbour, Guillermo Garcia-Manero, Gautam Borthakur, Tapan Kadia, Michael Rytting, Marina Konopleva, Hagop Kantarjian, Susan O'Brien. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 100(5):623-661, 2015.
58. Naval Daver, Jorge Cortes, Farhad Ravandi, Keyur P. Patel, Jan A. Burger, Marina Konopleva, Hagop Kantarjian. Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood 125(21):3236-3245, 2015.
59. Talha Badar, Philip A Thompson, Binsah George, Naval Daver, Gautam Borthakur, Jorge E Cortes, Marina Konopleva, Tapan Kadia, Zach Bohannan, Sherry Pierce, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian, Keyur P. Patel, Raja Luthra, Victoria Sukholutsky, Guillermo Garcia-Manero. Temporal Acquisition of FLT3-ITD or RAS Mutation at Transformation to AML from MDS: Clinical Implications. Blood 124(21):4631, 2014.
60. Naval Daver, Hagop M. Kantarjian, Susan O'Brien, Elias Jabbour, Sherry Pierce, Miranda Lim, Gautam Borthakur, Naveen Pemmaraju, Marina Konopleva, Courtney D. DiNardo, Farhad Ravandi, Guillermo Garcia-Manero, Jorge E. Cortes. Frequency and Impact of Molecular Response's with Nilotinib (Tasigna) in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)- Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). Blood 124(21):3156, 2014.
61. Elias Jabbour, Koji Sasaki, Naval Daver, Naveen Pemmaraju, Nitin Jain, Tapan M. Kadia, Courtney D. DiNardo, Gautam Borthakur, Marina Konopleva, Stefan H. Faderl, Susan O'Brien, Jorge Cortes, Hagop Kantarjian, Guillermo Garcia-Manero. Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy. Blood 124(21):534, 2014.
62. Naval Daver, Jorge E. Cortes, Elias Jabbour, Naveen Pemmaraju, Nitin Jain, Zeev Estrov, Steven M. Kornblau, Jan A. Burger, Hagop M. Kantarjian, Kate J. Newberry, Srdan Verstovsek. Ruxolitinib and Lenalidomide As a Combination Therapy for Patients with Myelofibrosis. Blood 124(21):1831, 2014.
63. Naval Daver, Hagop M. Kantarjian, Guillermo Garcia-Manero, Naveen Pemmaraju, Tapan M. Kadia, Courtney D. DiNardo, Nitin Jain, Gautam Borthakur, Elias Jabbour, Marina Konopleva, Jorge E. Cortes, Adam Craig, Farhad Ravandi. Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). Blood 124(21):385, 2014.
64. Talha Badar, Hagop M. Kantarjian, Gautam Borthakur, Guillermo Garcia-Manero, Michael Andreef, Marina Konopleva, Tapan M. Kadia, Naval Daver, William G. Wierda, Farhad Ravandi, Jorge E. Cortes. Improvement in Clinical Outcome of FLT3 Mutated AML Patients over the Last One and a Half Decade. Blood 124(21):949, 2014.
65. Tapan Kadia, Gautam Borthakur, Alessandra Ferrajoli, Naval Daver, Elias Jabbour, Naveen Pemmaraju, Srdan Verstovsek, Jan A. Burger, William G. Wierda, Marina Konopleva, Courtney D. DiNardo, Nitin Jain, Mark Brandt, CArla Tuttle, Xuemei Wang, Farhad Ravandi, Guillermo Garcia-Manero, Jorge E. Cortes, Hagop M. Kantarjian. Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML). Blood 124(21):3671, 2014.
66. Preestesh Jain, Hagop M. Kantarjian, Elias Jabbour, Gautam Borthakur, Naveen Pemmaraju, Naval Daver, Evguenia Gachimova, Alessandra Ferrajoli, Steven M. Kornblau, Farhad Ravandi, Susan O'Brien, Jorge E. Cortes. Ponatinib As Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood 124(21):4535, 2014.
67. Nitin Jain, Farhad Ravandi, Guillermo Garcia-Manero, Gautam Borthakur, Tapin Kadia, Elias Jabbour, Naveen Pemmaraju, Naval Daver, Courtney D. DiNardo, Marina Konopleva, Allison Pike, Carol Bivins, Sherry Pierce, Susan O'Brien, Jorge E. Cortes, Hagop M. Kantarjian. Phase I-II Study of Sequential Therapy with Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine (DAC-CIA) regimen) in Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood 124(21):5283, 2014.
68. Courtney D. DiNardo, Fleur M. Aung, Fernando Martinez, Naval Daver, Tapan Kadia, Nitin Jain, Elias Jabbour, Naveen Pemmaraju, Virgil M. Reddy, Guillermo Garcia-Manero, Jorge Cortes, Farhad Ravandi, Hagop M. Kantarjian, Benjamin Lichtiger, Emil J. Freireich. A Phase II Feasibility Study of Prophylactic White Cell Transfusions for the Preventio of Infection in AML Patients Undergoing Induction Therapy. Blood 124(21):1564, 2014.
69. Krisstina L. Gowin, Amylou Constance Dueck, Srdan Verstovsek, Naval Daver, Naveen Pemmaraju, Riccardo Valdez, Ruben A. Mesa. The Clinical Phenotype of Patients with Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis Whom Only Manifest WHO Grade 1 Fibrosis. Blood 124(21):3208, 2014.
70. Deborah A. Thomas, Susan O'Brien, Michael Rytting, Farhad Ravandi, Elias Jabbour, Alessandra Ferrajoli, Zeev Estrov, Guillermo Garcia-Manero, Jan A. Burger, William Wierda, Marina Konopleva, Michael Andreeff, Steven M. Kornblau, Srdan Verstovsek, Gautam Borthakur, Tapan Kadia, Rebecca Garris, Naveen Pemmaraju, Naval Daver, Nitin Jain, Jorge Cortes, Hagop M. Kantarjian. Incidence of Central Nervous System (CNS) Relapse in De Novo Adult Acute Lymphoblastic Leukemia (ALL). Blood 124(21):940, 2014.
71. Jasleen K. Randhawa, Kausar Jabeen Jabbar, Tapan Kadia, Gautam Borthakur, Naveen Pemmaraju, Naval Daver, Hagop M. Kantarjian, Jorge E Cortes, Katherine Hearn, Carlos I Bueso-Ramos, Guillermo Garcia-Manero. Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low - or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-kB Activation. Blood 124(21):1930, 2014.
72. Jasleen K. Randhawa, Hagop M. Kantarjian, Gautam Borthakur, Philip Alastair Thompson, Maria Konopleva, Naval Daver, Naveen Pemmaraju, ELias Jabbour, Tapan M Kadia, Zeev Estrov, Abhijit Ramachandran, Jamil Paradela, Michael Andreef, Mark Levis, Farhad Ravandi, Jorge E Cortes. Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations. Blood 124(21):389, 2014.
73. Elias Jabbour, Koji Sasaki, Naval Daver, Naveen Pemmaraju, Courtney D. DiNardo, Tapan Kadia, Darla Miller, Victoria Sukholutsky, Xuelin Huang, Gautam Borthakur, Zeev Estrov, Hagop M. Kantarjian, Guillermo Garcia-Manero. Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low-or Intermediate-1 Risk Myelodysplastic Syndrome (MDS). Blood 124(21):4640, 2014.
74. Polina Matre, Maryam Shariati, Juliana Velez, Yuan Qi, Sergej Konoplev, Xiaoping Su, Courtney D. DiNardo, Naval Daver, RAvi Majeti, Michael Andreeff, Steven M Chan, Marina Konopleva. Efficacy of Novel Glutaminase Inhibitor CB-839 in Acute Myeloid Leukemia. Blood 124(21):3763, 2014.
75. Monica Cabrero, Elias Jabbour, Naval Daver, Gautam Borthakur, Courtney D DiNardo, Jorge E Cortes, Zach Bohannan, Victoria Sukholutsky, Farhad Ravandi, Sherry Pierce, Tapan Kadia, Naveen Pemmaraju, Hagop M. Kantarjian, Guillermo Garcia-Manero. Discontinuation of HMA Therapy after Achieving Complete or Partial Response: Retrospective Analysis of Survival after Long-Term Follow up. Blood 124(21):4664, 2014.
76. Talha Badar, Hagop M Kantarjian, Susan O'Brien, Guillermo Garcia-Manero, Elias Jabbour, Rebecca Garris, Naveen Pemmaraju, Naval Daver, Farhad Ravandi, Jorge Cortes, Deborah A. Thomas. Clinical Outcome of De Novo Adult Acute Lymphoblastic Leukemia (ALL) with 11q23/Mixed Lineage Leukemia (MLL) Gene Rearrangements. Blood 124(21):5342, 2014.
77. Gautam Borthakur, Hagop M. Kantarjian, Susan O'Brien, Guillermo Garcia-Manero, Elias Jabbour, Naval Daver, Tapan Kadia, Rosilyn Gborogen, Marina Konopleva, Michael Andreeff, Farhad Ravandi. The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. Blood 124(21):388, 2014.
78. Koji Sasaki, Sara S. Strom, Susan O'Brien, Elias Jabbour, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, Naveen Pemmaraju, Naval Daver, Sherry R. Pierce, Hagop M. Kantarjian, Jorge E. Cortes. Chronic Myeloid Leukemia in Chronic Phase: Survival in the Era of Tyrosine Kinase Inhibitors Is Similar to That of the General Population in All Age Groups. Blood 124(21):1801, 2014.
79. Binsah George, Elias Jabbour, Monica Cabrero, Nitin Jain, Naval Daver, Farhad Ravandi, Gautam Borthakur, Zach Bohannan, Jorge E. Cortes, Michael J Keating, Susan O'Brien, Hagoop M. Kantarjian, Guillermo Garcia-Manero. Retrospective Analysis of Survival in Patients with Acute Erythroid Leukemia (AML-6) Treated with Conventional Chemotherapy Versus Hypomethylating Agents. Blood 124(21):2278, 2014.
80. Shyamala C. Navado, Guillermo Garcia-Manero, Francois Wilhelm, Katherine Hearn, Rosalie Odchimar-Reissig, Erin P. Demakos, Yesid Alvarado, Naval Daver, Courtney D. DiNardo, Marina Konopleva, Gautam Borthakur, Nozar Azarnia, Lewis R. Silverman. A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Blood 124(21):3252, 2014.
81. Monica Cabrero, Guillermo Garcia-Manero, Koji Sasaki, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Jorge E. Cortes, Zach Bohannan, Victoria Sukholutsky, Farhad Ravandi, Sherry Pierce, Tapan M Kadia, Naveen Pemmaraju, Betul Oran, Richard E Champlin, Hagop Kantarjian, Elias Jabbour. Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study. Blood 124(21):4666, 2014.
82. Phillip A Thompson, Michael J Keating, Christina Hinojosa, Susan C. Smith, Naval Daver, Nitin Jain, Jan A. Burger, Zeev Estrov, Susan O'Brien, William G. Wierda, Hagop M. Kantarjian, Alessandra Ferrajoli. Lenalidomide and Rituximab in Combination As Initial Treatement of Chronic Lymphocytic Leukemia: Initial Results of a Phase II Study. Blood 124(21):1988, 2014.
83. Chenyue W Hu, Amina A Qutub, Yihua Qiu, Suk Young Yoo, Nianxiang Zhang, Naval Daver, Maro Ohanian, Kevin Coombes, Steven M. Kornblau. Adhesion Signaling States in AML. Blood 124(21):2386, 2014.
84. Guillermo Garcia-Manero, Ellen K. Ritchie, Katherine Walsh, Michael Savona, Patricia Kropf, Casey O'Connell, Raoul Tibes, Naval Daver, Elias Jabbour, Scott Lunin, Todd L. Rosenblat, Karen Yee, Wendy Stock, Elizabeth A. Griffiths, Joseph R. Mace, Nikolai A. Podoltsev, Jesus G. Berdeja, Jean-Pierre Issa, Woonbok Chung, Sue Naim, Pietro Taverna, Yong Hao, Mohammad Azab, Hagop M. Kantarjian, Gail J. Roboz. First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood 124(21):529, 2014.
85. Guillermo Garcia-Manero, Xuelin Huang, Monica Cabrero, Courtney D. DiNardo, Naveen Pemmaraju, Naval Daver, Gautam Borthakur, William G. Wierda, Tapan Kadia, Yesid Alvarado, Jorge E. Cortes, Nitin Jain, Farhad Ravandi, Elias Jabbour, Mark Brandt, Troy Sneed, Victoria Sukholutsky, Sherry Pierce, Zachary Bohannan, Hagop M. Kantarjian. A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities. Blood 124(21):3277, 2014.
86. Naveen Pemmaraju, Hagop M. Kantarjian, Susan O'Brien, Gautam Borthakur, Farhad Ravandi, Srdan Verstovsek, Naval Daver. Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP). Blood 124(21):4565, 2014.
87. Adolfo Diaz Duque, Monica Cabrero, Farhad Ravandi, Naveen Pemmaraju, Gautam Borthakur, Hagop M. Kantarjian, Jorge E Cortes, Tapan M Kadia, Naval Daver, Elias Jabbour, Guillermo Garcia-Manero, Koji Sasaki. Long-Term Outcome of Chronic Myelomonocytic Leukema (CMML) Patients Treated with Hypomethylating Agents (HMA: A Single-Institution Experience. Blood 124(21):1924, 2014.
88. Koji Sasaki, Elias Jabbour, Naveen Pemmaraju,Naval Daver, Tapan M Kadia, Courtney D. DiNardo, Sherry Pierce, Gautam Borthakur, Hagop M. Kantarjian, Guillermo Garci-Manero. Predictive Factors for Response and Survival in Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMA) Failure: Primary Resistance (PriRes) Vs. Secondary Resistance (SecRes). Blood 124(21):1922, 2014.
89. Keyur Patel, Mark Routbort, Graciela Noguera-Gonzalez, Hagop M Kantarjian, Elias Jabbour, Gautam Borthakur, Courtney D. DiNardo, Zee Estrov, Naval Daver, Willam Wierda, Nitin Jain, Susan O'Brien, Marina Konopleva, Jorge E Cortes, Naveen Pemmaraju, Yesid Alvarado, Carlos E Bueso-Ramos, Raja Luthra, Rajesh Singh, Sherry Pierce, L Jeffrey Medirios, Zachary Bohannan, Xuelin Huang, Guillermo Garcia-Manero. Multigene Mutational Clinical Profiling Using Next Generation Sequencing in a Cohort of 451 Patients with MDS: Impact on Clinical Outcomes. Blood 124(21):4658, 2014.
90. Elias Jabbour, Koji Sasaki, Mikkael A. Sekeres, Rami S Komrokji, David P Steensma, Amy E SeZern, Roboz J Gail, Naval Daver, Naveen Pemmaraju, Tapan Kadia, Courtney D. DiNardo, Xuemei Wang, Graciela Nogueras-Gonzalez, Gautam Borthakur, Zeev Estov, Hagop M Kantarjian, Guillermo Garcia-Manero. Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium. Blood 124(21):4641, 2014.
91. Talha Badar, Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Jorge E. Cortes, Naveen Pemmaraju, Daver NG, Srdan Verstovsek. Decitabine therapy for myeloproliferative neoplasm in accelerated (MPN-AP) or blastic (acute myeloid leukemia; MPN-AML) phase. 2014 ASCO Annual Meeting, 2014.
92. Tapan M. Kadia, Jorge E. Cortes, Gautam Borthakur, Guillermo Garcia-Manero, Elias Jabbour, Alessandra Ferrajoli, Srdan Verstovsek, Farhad Ravandi, Naveen Pemmaraju, Naval Guastad Daver, Marina Konopleva, Xuemei Wang, Hagop M. Kantarjian. Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients with AML. 2014 ASCO Annual Meeting, 2014.
93. Simon Abi Aad, Daver NG, Paolo Strati, Jorge E. Cortes, Guillermo Garcia-Manero, Michael Mathisen, Farhad Ravandi, Tapan M. Kadia, Susan Mary O'Brien, Carol Bivins, Sherry Pierce, Hagop M. Kantarjian, Elias Jabbour. ASCO 2014: High prevalence of FLT-3 ITD mutations in patients (pts) with AML who present with CNS relapse. 2014 ASCO Annual Meeting, 2014.
94. Aditya Shetty, Carlos E. Bueso-Ramos, Jorge E. Cortes, Gautam Borthakur, Sherry Pierce, Tapan M. Kadia, Naval Daver, Deborah A. Thomas, Hagop M. Kantarjian, Farhad Ravandi. Outcomes of patients (pts) with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) with bone marrow necrosis (BMN) at initial diagnosis. 2014 ASCO Annual Meeting, 2014.
95. Michael Andreeff, Gautam Borthakur, Zhihong Zeng, Mary A. Kelly, Rui-Yu Wang, Teresa J. McQueen, Yihua Qiu, Duncan Mak, Jan Andreas Burger, Daver NG, Naveen Pemmaraju, Tapan M. Kadia, Elias Jabbour, Sherry Pierce, Farhad Ravandi, Guillermo Garcia-Manero, Susan Mary O'Brien, Jorge E. Cortes, Hagop M. Kantarjian, Marina Konopleva. Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients. 2014 ASCO Annual Meeting, 2014.
96. Naveen Pemmaraju, Deborah A. Thomas, Hagop M. Kantarjian, Jorge E. Cortes, Joseph Khoury, John T Manning, L Jeffrey Medeiros, Susan Mary O'Brien, Daver NG, Sherry Pierce, Guillermo Garcia-Manero, Elias Jabbour, Nitin Jain, Muzaffar H. Qazilbash, Stefan Faderl, Arthur E. Frankel, Marina Konopleva. Characteristics of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Male predominance, propensity for extramedullary involvement, and poor outcomes. 2014 ASCO Annual Meeting, 2014.
97. Hagop M. Kantarjian, Elias Jabbour, Karen Yee, Patricia Kropf, Casey O'Connell, Wendy Stock, Raoul Tibes, David Rizzieri, Katherine Walsh, Elizabeth A Griffiths, GAil J. Roboz, Michael Savona, THomas Ervin, Nikolai Podoltsev, Naveen Pemmaraju, Naval Daver, Guillermo Garcia-Manero, Gautam Borthakur, William G. Wierda, Farhad Ravandi, Jorge E. Cortes, Joseph Brandwein, Olatoyosi Odenike, Eric J. Feldman, Woonbok Chung, Sue Naim, Gavin Choy, Petro Taverna, Yong Hao, George Dimitrov, Mohammad Azab, Jean-Pierre Issa. First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating AGent (HMA), In Adult Patients With Acute Myeloid dLeukemia (AML). Blood 122(21):497, 2013.
98. Tapan M. Kadia, Naval Daver, Fiona Virani, ELias Jabbour, Sherry Pierce, Naveen Pemmaraju, Alfonso Quintas-Cardama, Gautam Borthakur, Susan O'Brien, Hagop M. Kantarjian, Jorge E. Cortes. Incidence, Clinical Characteristics, and Prognostic Significance Of Chromosome 3q Abnormalities In Patients With CML Blast Phase. Blood 122(21):2714, 2013.
99. Michael E. Rytting, Deborah A. Thomas, Susan O'Brien, Kurt Schroeder, Rebecca Garris, Jorge E. Cortes, Farhad Ravandi, Naveen Pemmaraju, Naval Daver, Stefan H. Faderl, Anna R.K. Franklin, Gautam Borthakur, Steven M. Kornblau, Hagop M. Kantarjian. Augmented Berlin-Frankfurt-Muenster Based Therapy For Young Adults With Acute Lymphoblastic Leukemia (ALL). Blood 122(21):1400, 2013.
100. Guillermo Garcia-Manero, Tapan M. Kadia, Naval Daver, Elias Jabbour, Nitin Jain, Jorge E. Cortes, Zeev Estrov, Gautam Borthakur, Xiao Q Dong. A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplasitc Syndromes (MDS). Blood 122(21):2751, 2013.
101. Jorge E. Cortes, Gautam Borthakur, Naveen Pemmaraju, Naval Daver, Alfonso uintas-Cardama, Farhad Ravandi, Evguenia Gachimova, Zeev Estrov, Elias Jabbour. Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP). Blood 122(21):1483, 2013.
102. Elias Jabbour, Hagop M. Kantarjian, Wei Qiao, Paolo Strati, navira F Khan, Jorge E. Cortes, Daniela Hoehn, Jianhua Hu, Susan Obrien, Jeffrey Bryan, Hillary Prescott, Courtne D. DiNardo, Naval Daver, Tapan M. Kadia, Guellermo Garcia-Manero. Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplasic Syndromes (MDS) Treated With Hypomethylating Agents (HMA). Blood 122(21):2801, 2013.
103. Gautam Borthakur, Srdan Verstovsek, Elias Jabbour, Jairo Matthews, Tapan M. Kadia, Naval Daver, Hagop M. Kantarjian, Jorge Cortes. Eltrombopag For The Management Of Thrombocytopenia Associated With Tyrosine Kinase Therapy In Patients With Chroniv Myeloid Leukemia and Myelofibrosis. Blood 122(21):4022, 2013.
104. Preetesh Jain, Hagop Kantarjian, Keyur P. Patel, Elias Jabbour, Naval Daver, Sherry Pierce, Ohad Benjamini, Gautam Borthakur, Courtney D. DiNardo, Stefan H. Faderl. Incidence, Clinical Characteristics, and Prognostic Relevance Of Clonal T-Cell Receptor Positive (TCR*) Populations In Patients With Myelodysplastic Syndrome (MDS). Blood 122(21):5231, 2013.
105. Koichi Takahashi, Elias Jabbour, Farhad Ravandi, Gautam Borthakur, Jorge E. Cortes, Tapan Kadia, Susan O'Brien, Deborah A. Thomas, Stefan Faderl, Joyce Bass, William G. Wierda, Naval Daver, Courtney D. DiNardo, Sherry Pierce, Mark Brandt, Hagop M. Kantarjian, Guillermo Garcia-Manero. A Phase II Expansion Study Of Vorinostat In Combination With Idarubicin and Cytarabine For Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations. Blood 122(21):2684, 2013.
106. Naveen Pemmaraju, Dhaval Shah, Hagop M. Kantarjian, Verena WAgner, Robert Z. Orlowski, Guillermo Garcia-Manero, Farhad Ravandi, Sherry Pierce, Koichi Takahashi, Naval Daver, Aziz Nazha, Srdan Verstovsek, Elias J. Jabbour, Marcos J de Lima, Richard E Champlin, Jorge E. Cortes, Muzaffar H. Qazilbash. Characteristics and Outcomes Of Patients (pts) With Multiple Myeloma (MM) WHo Develop Therapy (t)-Related Myelodysplstic Syndrome (MDS), t-Chronic Myelomonocytic Leukemia (CMML), Or t-Acute Myeloid Leukemia (AML). Blood 122(21):1424, 2013.
107. Paolo Strati, Hagop M. Kantarjian, Aziz Nazha, Gautam Borthakur, Naval Daver, Tapan M. Kadia, Zeev Estrov, Guillermo Garcia-Manero, Trivikram Rajkhowa, Farhad Ravandi, Menda Durand, Mark Levis, Jorge E. Cortes. Early Results Of a Phase I/II Trial Of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) For Patients (Pts) With Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood 122(21):3949, 2013.
108. Aziz Nazha, Hagop M. Kantarjian, Elias Jabbour, Courtne D. DiNardo, Gautam Borthakur, Naval Daver, Stefan H. Faderl, Jing Ning, Wei. Outcome Of Patients With Myelodysplasic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating AGents Versus Intensive Chemotherapy. Blood 122(21):2788, 2013.
109. Courtney D. DiNardo, Hagop M Kantarjian, Farhad Ravandi, Marina Konopleva, Tapan M. Kadia, Gautam Borthakur, Naval Daver, Menda Durand, Silvia Rivera, Alfonso Quintas-Cardama, Guillermo Garcia-Manero. A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS. Blood 122(21):2698, 2013.
110. Maro Ohanian, Mark Levis, Stefan H. Faderl, Guillermo Garcia-Manero, Elias Jabbour, Naval Daver, Sara E Dellasala, Sherry Pierce, Jan A. Burger, Jorge E. Cortes, Hagop M. Kantarjian. Final Report Of Phase II Study Of Sorafenib and 5-Acacytidine In Patients With Relapsed Or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation. Blood 122(21):3934, 2013.
111. Steven M. Kornblau, Chenyu W. Hu, Suk Young Yoo, Yihua Qiu, Nianxiang Zhang, Gautam Borthakur, Naval Daver, Amina A. Qutub, Kevin R. Coombes,. Classification Of Acute Myelogenous Leukemia (AML) Based On Functionally Related Proteins Groups. Blood 122(21):492, 2013.
112. Courtney D. DiNardo, Naval Daver, Nitin Jain, Naveen Pemmaraju, Carlos E. Bueso-Ramos, Cheng Yin, Sherry R. Pierce, Elias Jabbour, Alfonso Quintas-Cardamo, Jorge E. Cortes, Hagop M. Kantarjian, Guillermo Garcia-Manero, Srdan Verstovsek. Myelodysplastic/Meloprliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural Hisory and Clinical Outcome By Therapeutic Approach. Blood 122(21):2825, 2013.
113. Aziz Nazha, Guillermo Garcia-Manero, Hagop M. Kantarjian, Farhad Ravandi, Gautam Borthakur, Tapan M. Kadia, Elias Jabbour, Naveen Pemmaraju, Naval Daver, Courtney D. DiNardo, Darla Miller, Stefan H. Faderl. CLofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy. Blood 122(21):1525, 2013.
114. Talha Badar, Gloria Mattiuzzi, Hagop M. Kantarjian, Farhad Ravandi, Naval Daver, Guillermo Garcia-Manero, Tapan M. Kadia, Elias J. Jabbour, Gautam Borthakur, Jorge E. Cortes. Phase II, Open Label, Randomized Comparative Trial Of Ondansetron Alone Versus The Combination Of Ondansetron Plus Aprepitant For the Prevention of Nausea and Vomiting In Patients (Pts) With Hematological Malignancies Receiving Regimens Containing High Dose Cytarabine. Blood 122(21):3887, 2013.
115. Daver NG, Naqvi K, Pierce S, Kadia T, Dinardo C, Ravandi F, Jabbour E, Nazha A, Borthakur G, Pemmarajau N, Brandt M, O’Brien S, Cortes J, Kantarjian H, Garcia-Manero G. Effect Of Comorbidities In Myelodysplastic Syndrome By Revised-IPSS and Age. 2013 ASH Annual Meeting and Exposition. Blood 15, 2013.
116. Daver NG, Kantarjian H, Thomas D, Rytting M, Ravandi F, Jain N, Cortes J, Kar J, Culotta K, Garris R, Richie M, Lu H, Konopleva M. A Phase I/II Study Of Hyper-CVAD Plus Everolimus In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia . 2013 ASH Annual Meeting and Exposition. Blood 15, 2013.
117. Daver NG, Kantarjian H, Faderl S, Garcia-Manero G, O’Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Kadia T, Cortes J, Ravandi F. Clinical Characteristics and Outcomes In Patients With Acute Promyelocytic Leukemia (APL) and Hyperleukocytosis.2013 ASH Annual Meeting and Exposition. Blood 15, 2013.
118. Tapan M. Kadia, Naval Daver, Farhad Ravandi, Elias Jabbour, Naveen Pemmaraju, Sherry Pierce, Jorge E. Cortes, Hagop M. Kantarjian. Results of omacetaxine plus low-dose cytarabine (LD-araC) in older patients with acute myeloid leukemia (AML). 2013 ASCO Annual Meeting, 2013.
119. Cecilia Ysabel Arana Yi, Gautam Borthakur, Peter F. Thall, Andrew L. Coveler, Farhad Ravandi, Elias Jabbour, Stefan Faderl, Deborah A. Thomas, Jorge E. Cortes, Tapan M. Kadia, Steven Mitchell Kornblau, Naval Daver, Naveen Pemmaraju, Hoang Q. Nguyen, William R. Wilson, Teresa J. Melink, John Gutheil, Hagop M. Kantarjian, Elihu Estey, Marina Konopleva. Final report of phase I/II study of PR104, a hypoxia-activated pro-drug, in relapsed/refractory acute leukemia. 2013 ASCO Annual Meeing, 2013.
120. Gautam Borthakur, Michael G. Rosenblum, Moshe Talpaz, Naval Daver, Farhad Ravandi, Stefan Faderl, Emil J. Freireich, Tapan Kadia, Guillermo Garcia-Manero, Hagop Kantarjian, Jorge E. Cortes. Phase 1 Study of an Anti-CD33 Immunotoxin, Humanized Monoclonal Antibody M195 Conjugated to Recombinant Gelonin (HUM-195/RGEL), in Patients with Advanced Myeloid Malignancies. Haematologica 98(2):217-221, 2013.
121. Farhad Ravandi, Mona Lisa Alattar, Michael R. Grunwald, Michelle A. Rudek, Trivikram Rajkhowa, Mary Ann Richie, Sherry Pierce, Daver NG, Guillermo Garcia-Manero, Stefan Faderl, Aziz Nazha, Marina Konopleva, Gautam Borthakur, Jan Burger, Tapan Kadia, Sara Dellasala, Michael Andreeff, Jorge Cortes, Hagop Kantarjian, Mark Levis. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 121(23):4655-4662, 2013.
122. Daver NG, Kantarjian H, Garcia-Manero G, Estrov Z, Konopleva M, Burger J, O'Brien S, Ferrajoli A, Verstovsek S, Kadia T, Jabbour E, Faderl S, Diaz-Pines-Mateo M, Pemmaraju N, Pierce S, Cortes JE, Borthakur G. Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. 2012 ASH Annual Meeting. Blood 120, 2012.
123. Kadia T, Cortes J, Thomas D, Ravandi F, Pemmaraju N, Daver NG, Quintás-Cardama A, Baccus M, Garris R, Jabbour E, Kantarjian H, Borthakur G. A Phase II Study of Methotrexate (M), Vincristine (O), Pegylated L-Asparaginase (pA), and Dexamethasone (MOpAD) in Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL). 2012 ASH Annual Meeting. Blood 120, 2012.
124. Nazha A, Ravandi F, Kantarjian H, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Andreeff M, Estrov Z, Daver NG, Pemmaraju N, Du M, Brandt M, Faderl S. Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). 2012 ASH Annual Meeting. Blood 120, 2012.
125. Jain P, Kantarjian H , Thomas D A., Ravandi F, Kadia T M., Burger J A., Borthakur G, Cortes J E. , Naval Daver , Jabbour E J., Koller C A. , Konopleva M , Pemmaraju N, Kelly M A. , Garris R, O'Brien S, Faderl S. Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL). 2012 ASH Annual Meeting. Blood 120, 2012.
126. Strati P, Kantarjian H, Cortes J E., Ravandi F, Pemmaraju N, Garcia-Manero G, Kadia T M., Jabbour E J., Nazha A, Borthakur G, Faderl S, Quintás-Cardama A, Daver NG. Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21. 2012 ASH Annual Meeting. Blood 120, 2012.
127. Alattar M, Kantarjian H, Cortes J E., Kadia T, Borthakur G, Ohanian, M, Ravandi F, Garcia-Manero G, Quintas-Cardamas A, Jabbour E, Daver NG, Pierce S, Brandt M, Faderl S, Pemmaraju N. Incidence and Outcomes of a Rare Translocation t(3,5) in Patients (pts) with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).2012 ASH Annual Meeting. Blood 120, 2012.
128. Jabbour E, Daver NG , Dong T (Xiao Qin) , Kadia T, O'Brien S, Cortes J E., Ravandi F, Pemmaraju N, Ghanem H, Faderl S, Borthakur G, Kantarjian H, Garcia-Manero G. Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure. 2012 ASH Annual Meeting. Blood 120, 2012.
129. Mathisen M, Kantarjian H, Ravandi F, Pemmaraju N, Garcia-Manero G, Cortes J, O'Brien S, Quintas-Cardama A, Ghanem H, Naval Daver, Pierce S, Lira C, Faderl S, Jabbour E. Updated Results of a Phase I/II, Randomized Study of Clofarabine Combined with Idarubicin and Cytarabine (CIA) or Fludarabine Combined with Idarubicin and Cytarabine (FIA) for the Treatment of Patients (pts) with Newly Diagnosed or Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML). 2012 ASH Annual Meeting. Blood 120, 2012.
130. Takahashi K, Pemmaraju N, Beran M, Quintás-Cardama A, Cortes J E., Ravandi F, Faderl S, Verstovsek S, Kadia T M., Borthakur G, Jabbour E J., Naval Daver, Estrov Z, Pierce S, Garcia-Manero G. Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML). 2012 ASH Annual Meeting. Blood 120, 2012.
131. Ghanem H, Garcia Manero G, Faderl S, Takahashi K, Ravandi F, Cortes J E., O'Brien S, Daver NG, Katragadda L, Pemmaraju N, Pierce S, Quintás-Cardama A, Kadia T, Kantarjian H M., JabbourE J.. Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure.2012 ASH Annual Meeting. Blood 120, 2012.
132. Jain P, Kantarjian H M., Faderl S, Patel K P., Garcia Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T M., Daver NG, Nazha A, Luthra R, Pierce S, Cortes J E., Ravandi F. Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia. 2012 ASH Annual Meeting. Blood 120, 2012.
133. Ravandi F, Patel K P., Luthra R, Pierce S, Borthakur G, Jabbour E J., Kadia T M., Pemmaraju N, Daver NG, Konopleva M, Faderl S, Garcia-Manero G, Cortes J E., Kantarjian H M.. Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents (± Histone Deacetylase Inhibitors).2012 ASH Annual Meeting. Blood 120, 2012.
134. Pemmaraju N, Thomas D, Kantarjian H M., Cortes J E., Manning John T., Medeiros l J., O'Brien S, Daver NG, Nazha A, Pierce S, Garcia-Manero G, Jabbour E, Faderl S. Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm. 2012 ASH Annual Meeting. Blood 120, 2012.
135. Ravandi F, Alattar M L., Levis M J., Garcia-Manero G., Richie M A., Daver NG, Faderl S, Andreeff M, Borthakur G, Burger J A., Kadia T M., Grunwald M R., Dellasala S E., Cortes J E., Kantarjian H M. 2012 ASH Annual Meeting. Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation. 2012 ASH Annual Meeting. Blood 20, 2012.
136. Quintás-Cardama A, Kantarjian H M., Ravandi F, Foudray C, Pemmaraju N , Kadia T M. , Borthakur G, Naval Daver, Faderl S, Jabbour E, Cortes J E., Garcia-Manero G. Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome. 2012 ASH Annual Meeting. Blood 120, 2012.
137. Kazmi S, Kantarjian H M., Tran K, Cortes J E., Ravandi F, Borthakur G, Jabbour E, Faderl S, Garcia-Manero G, Kadia T M., Daver NG, Pierce S, Nazha A, Quintas-Cardama A, Pemmaraju N. Cytogenetic and Molecular Characterization of Sweet's Syndrome in Patients with Acute Myeloid Leukemia. 2012 ASH Annual Meeting. Blood 120, 2012.
138. Ghanem H, Kantarjian H M., Faderl S, Jabbour E, Naval Daver, Pierce S, Brandt M, Quintás-Cardama A, Luthra R, Garcia-Manero G, Cortes J E., Ravandi F. Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) On Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) with Acute Promyelocytic Leukemia (APL) Treated with All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO). 2012 Annual Meeting. Blood 120, 2012.
139. Nazha A, Kantarjian H M., Cortes J E., Faderl S, Pierce S, Daver NG, Pemmaraju N, Ravandi F, Borthakur G, Kadia T M., Quintas-Cardama A, Garcia-Manero G. Outcome of Patients with Myelodysplastic Syndrome (MDS) with Bone Marrow (BM) Blasts Between 10 to 30% Treated with Hypomethylating Agents Versus Intensive Chemotherapy. 2012 ASH Annual Meeting. Blood 120, 2012.
140. Daver NG, Kantarjian H M., Garcia-Manero G, Cortes J E., Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T M., Burger J A., Konopleva M, Brandt M, Huang X, Jabbour E. Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia. 2012 ASH Annual Meeting. Blood 120, 2012.
141. Faderl S, Garcia-Manero G, Ravandi F, Cortes JE, Estrov Z, Borthakur G, O'Brien S, Kadia TM, Konopleva M, Daver NG, Brandt M, Schroeder H, Kantarjian H M. A Randomized Study of Low Dose Oral Clofarabine 10 Mg Versus 20 Mg (flat dose) Daily x 5 for Patients with Higher-Risk Myelodysplastic Syndrome (MDS). Blood 120, 2012.
142. Aziz Nazha, Jorge Cortes, Stefan Faderl, Sherry Pierce, Naval Daver, Tapan Kadia, Gautam Borthakur, Raja Luthra, Hagop Kantarjian, Farhad Ravandi. Activating Internal Tandem Duplication Mutations of the Fms-Like Tyrosine Kinase-3 (FLT3-ITD) at Complete Response and Relapse in Patients with Acute Myeloid Leukemia. Haematologica 97(8):1242-1245, 2012.
143. Pavan Kumar Bhamidipati, Naval Daver, Hagop Kantarjian, Sherry Pierce, Roshni Daver, Jorge E. Cortes, Farhad Ravandi, Michael Mathisen, Naveen Pemmaraju, Aziz Nazha, Tapan M. Kadia, Elias Jabbour, Gautam Borthakur, Stefan Faderl, Guillermo Garcia-Manero. FLT3 mutations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). 2012 ASCO Annual Meeting, 2012.
144. Naveen Pemmaraju, Deborah A. Thomas, Hagop Kantarjian, Susan Mary O'Brien, Naval Daver, Aziz Nazha, Sherry Pierce, Guillermo Garcia-Manero, Jorge E. Cortes, Stefan Faderl. Analysis of outcomes of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN). 2012 ASCO Annual Meeting, 2012.
145. Michael Mathisen, Hagop Kantarjian, Stefan Faderl, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia, Naval Daver, Susan Mary O'Brien, Stephan Joseph Dorkhom, Sherry Pierce, Cynthia Lira, Jorge E. Cortes, Elias Jabbour. Interim results of a phase I/II randomized study of clofarabine, idarubicin, and cytarabine (CIA) versus fludarabine, idarubicin, and cytarabine (FIA) for newly diagnosed or relapsed patients (pts) with acute myeloid leukemia (AML). 2012 ASCO Annual Meeting, 2012.
146. Mona Lisa Alattar, Hagop Kantarjian, Jan Andreas Burger, Mary Ann Richie, Guillermo Garcia-Manero, Marina Konopleva, Stefan Faderl, Gautam Borthakur, Naval Daver, Tapan M. Kadia, Jorge E. Cortes, Farhad Ravandi. Response rates in patients with relapsed/refractory acute myeloid leukemia with FLT3-ITD mutation using 5-azacitadine plus sorafenib. 2012 ASCO Annual Meeting, 2012.
147. Daver NG, De Lima M, Kantarjian H, Ravandi F, Bilen M, Pierce S, Khouri I, Dorkhom S, Giralt S, Garcia-Manero G, Nazha A, Mathisen M, Pemmaraju N, Cortes JE, Faderl S, Jabbour E. Allogeneic stem cell transplant as initial salvage for patients with acute myeloid leukemia(AML) refractory to high-dose cytarabine-based induction chemotherapy. 2012 ASH Annual Meeting. Journal of Clinical Oncology 30(15), 2012.
148. Bhamidipati P, Daver NG, Kantarjian H, Pierce S, Daver R, Cortes JE, Ravandi F, Mathisen M, Pemmaraju N, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Garcia-Manero G. FLT3 mutations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). 2012 ASH Annual Meeting. Journal of Clinical Oncology 30(15), 2012.
149. Pemmaraju N, Thomas DA, Kantarjian H, O'Brien S, Daver NG, Nazha A, Pierce S, Garcia-Manero G, Cortes JE, Faderl S. Analysis of outcomes of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN). 2012 ASH Annual Meeting. Journal of Clinical Oncology 30(15), 2012.
150. Kadia T, Jabbour E, Pemmaraju N, Faderl S, Borthakur G, Thomas DA, Daver NG, Ravandi F, Kantarjian H. Phase II Study of Omacetaxine (OM) & Low Dose AraC (LDAC) in Older Patients with Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). 2012 ASH Annual Meeting. Journal of Clinical Oncology 30(15), 2012.
151. Mathisen M, Kantarjian H, Faderl S, Garcia-Manero G, Ravandi F, Kadia T, Daver NG, O'Brien S, Dorkhom S, Pierce S, Lira C, Cortes JE, Jabbour E. Interim results of a phase I/II randomized study of clofarabine, idarubicin, and cytarabine (CIA) versus fludarabine, idarubicin, and cytarabine (FIA) for newly diagnosed or relapsed patients (pts) with acute myeloid leukemia. 2012 ASH Annual Meeting. Journal of Clinical Oncology 30(15), 2012.
152. Alattar M, Kantarjian H, Burger J, Richie M, Garcia-Manero G, Konopleva M, Faderl S, Borthakur G, Daver NG, Kadia T, Cortes JE, Ravandi F. Response rates in patients with relapsed/refractory acute myeloid leukemia with FLT3-ITD mutation using 5-azacitadine plus sorafenib. 2012 ASH Annual Meeting. Journal of Clinical Oncology 30(15), 2012.
153. Daver NG, Kantarjian H, Garcia - Manero G, Cortes JE, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, huang X, Jabbour E. Twice Daily Fludarabine and Cytarabine Combination is Effective in Patients with Relapsed / Refractory Acute Myeloid Leukemia, High - Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia. Blood 118, 2011.
154. Daver NG, Kantarjian H, Garcia-Manero G, Borthakur G, Ravandi F, Kadia T, Estrov Z, Konopleva M, Faderl S, Cortes JE. AR-67, a DNA Topo-Isomerase I Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase II Trial of Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML). Blood 118, 2011.
155. Nazha A, Bhatt VR, Nogueras-Gonzalez G, Kadia T, Cortes JE, Daver NG, Garcia-Manero G, Kantarjian H, Borthakur G. Prognostic Implication of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype (MK) in Patients with Acute Myeloid Leukemia (AML) and Complex Cytogenetics. Blood 118, 2011.
156. Garcia-Manero G, Daver NG, Borthakur G, Konopleva M, Ravandi F, Wierda W, Estrov Z, Faderl S, Kadia T, Rey K, Cheung C, Kantarjian H. Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML). Blood 118, 2011.

Book Chapters

1. Daver NG, Udden M. Acute Lymphoblastic Leukemia. In: Hematology Oncology.